US Pat. No. 10,791,712

PET NAIL CLIPPER

Alexandre Contreras, Hom...

1. A pet nail clipper comprising:a first arm comprising a first handle portion and a first cutting portion comprising a first blade;
a second arm comprising a second handle portion and a second cutting portion comprising a second blade, wherein the second handle portion includes a gripping portion and has a receptacle bracket that extends laterally out from the second handle portion forward of the gripping portion;
a pivot bolt pivotally attaching the first arm and the second arm together in between the first and second handle portions and the first and second cutting portions; and
a receptacle secured within the receptacle bracket wherein the receptacle has an entrance designed to receive a pet's nail into a styptic substance contained within the receptacle.

US Pat. No. 10,791,711

APPARATUSES AND METHODS FOR PROTECTING SURFACES FROM PET-CAUSED DAMAGE

PEACHTREE PET LLC, Atlan...

1. A method of discouraging pets from resting on a seating portion of a piece of furniture, the method comprising:providing at least two surface protectors stacked relative to one another in a fully overlapped configuration, each of the at least two surface protectors comprising:
(i) a rigid planar base portion having a defined perimeter surrounding the rigid planar base portion and defining a top surface and a bottom surface; and
(ii) a plurality of protrusions extending away from the top surface of the rigid planar base, wherein the plurality of protrusions are spaced on the top surface of the rigid planar base such that an animal paw does not fit between the plurality of protrusions, wherein the plurality of protrusions collectively define an irregular surface that discourages pets from resting on the top surface of the planar base portion;
separating a first surface protector and a second surface protector of the at least two surface protectors relative to one another, such that the first and second surface protectors are no longer in the fully overlapped configuration;
positioning the first surface protector on a first section of the seating portion of the piece of furniture;
positioning the second surface protector on a second section of the seating portion of the piece of furniture, the first and second sections at least partially overlapping one another such that the rigid planar base portion of the second surface protector partially overlaps the rigid planar base portion of the first surface protector; and
connecting the first surface protector and the second surface protector such that a first subset of the plurality of protrusions of the first surface protector extend above the top surface of the planar base portion of the second surface protector and a second subset of the plurality of protrusions of the first surface protector are positioned outside of the defined perimeter of the second surface protector.

US Pat. No. 10,791,710

SCENT TRAINING ASSEMBLY

1. An assembly for scent training an animal, said assembly comprising:a bowl body comprising at least one side wall and a base defining a food receiving trough region,
a raised scent distribution column extending from said base, wherein said food receiving trough region surrounds said raised scent distribution column,
said raised scent distribution column comprising an at least partially hollow interior portion defined by at least one wall and a top surface, said top surface comprising a plurality of scent distribution holes disposed there through, and
a scent pod removably retained within said at least partially hollow interior portion of said scent distribution column, said scent pod comprising a pocket with an at least partially open top communicative with said plurality of scent distribution holes disposed on said top surface of said raised scent distribution column, wherein a scent will naturally permeate from within said pocket of said scent pod and through said plurality of holes disposed on said top surface of said raised scent distribution column.

US Pat. No. 10,791,709

GROOMING SOCK FOR ANIMALS

1. A grooming sock for placement on the paw of an animal to prevent the animal's long paw hair or fur from being caught or tangled in a rotary grooming tool during trimming of the animal's nails, the grooming sock comprising:a bottom layer formed of mesh fabric material having a plurality of adjacent openings and a mesh size in the range of from about 3 mm to about 7 mm mesh, said bottom layer having a contiguous U-shaped perimeter with a contiguous straight end, an opposed semicircular end, and laterally opposed sides;
a top layer formed of non-mesh fabric material having a contiguous U-shaped perimeter with a contiguous straight end, an opposed semicircular end, and laterally opposed sides;
said mesh bottom layer said top layer sewn together along their said semicircular end and laterally opposed sides, respectively, to define an interior having an open end;
said interior configured to receive and accommodate the paw of the animal with said top layer of non-mesh fabric material covering a top portion of the paw, said bottom layer of mesh fabric material covering a bottom portion of the paw, and said plurality of openings of said recited mesh size of said mesh fabric material allowing each of the animal's nails to pass through selected openings, respectively, and simultaneously retain the long paw hair or fur surrounding the nails within said interior to prevent the surrounding paw hair or fur from being caught or tangled in the rotary grooming tool during trimming of the animal's nails; and
at least one loop secured at one end to a lateral side edge of said grooming sock of sufficient length to wrap around said sock and the animal's paw to secure said sock in place on the animal's paw during the trimming operation.

US Pat. No. 10,791,708

METHOD SYSTEM AND APPARATUS FOR DETERMINING FINISH TIME AND RANKING OF ANIMALS IN COMPETITIVE ENVIRONMENTS

Lip Chip, LLC, Austin, T...

1. A method for determining which animal reached a finish line first, comprising:Installing a first tag in a nose of a first animal;
Transmitting a first location signal from said first tag;
Installing a second tag in a nose of a second animal;
Transmitting a second location signal from said second tag;
Receiving said first location signal and said second location signal; and
Determining which of said first tag and said second tag reached said finish line first.

US Pat. No. 10,791,707

FEEDING SYSTEM AND METHOD FOR FEEDING NON-HUMAN ANIMALS

LELY PATENT N.V., Maassl...

1. A feeding system to feed non-human animals, comprising:a first autonomous mobile device; and
a second autonomous mobile device,
wherein the first autonomous mobile device includes:
a feed holder to receive feed through a first opening;
a feed mixer to mix the received feed;
a feed dispenser configured to dispense feed to the second autonomous mobile device through a second opening spaced from the first opening;
a control system for controlling the first autonomous mobile device and the second autonomous mobile device, the control system receiving a feed request from the second autonomous mobile device and sending a command to the first autonomous mobile device to deliver feed to the second autonomous mobile device after receiving the feed request from the second autonomous mobile device; and
a feed storage location, a feed discharge location and a feed preparation device,
wherein the feed preparation device is configured to deliver feed from the feed storage location to the feed discharge location to fill the first autonomous mobile device,
wherein the second autonomous mobile device includes a feed holder to receive feed from the first autonomous mobile device, and
wherein the second autonomous mobile device is smaller than the first autonomous device.

US Pat. No. 10,791,706

DOUBLE TANK MILK SUPPLY SYSTEM FOR PROVIDING A CONTINUOUS SUPPLY OF MILK OR MILK PRODUCTS

1. A double tank milk supply system, for providing a continuous supply of milk or a milk product, the double tank milk supply system comprising:a pair of tanks, the pair of tanks having a first tank and a second tank, each tank configured to hold a sequence of fluids including: a milk product, a hot cleaning solution, and a cold water wash;
a valve system, configured to independently control each of: the sequence of fluids exiting the first tank, and the sequence of fluids exiting the second tank;
an automatic empty system, which automatically configures the valve system to dispense the milk product from the second tank when the first tank is empty, and to dispense the milk product from the first tank when the second tank is empty, thereby providing continuous dispensing of the milk product;
a cooling system, which independently and alternately cools the first tank and then the second tank;
an automatic washing system, which automatically washes the first tank when the first tank is empty, and which automatically washes the second tank when the second tank is empty;
an agitation system, which independently agitates the milk product in the first tank, and independently agitates the milk product in the second tank;
a wash pump to pump out the hot cleaning solution from a set of outgoing washing pipes;
a tank insulation layer, configured to provide thermal insulation for the first tank and for the second tank;
a data input and display device configured to accept a user's input data, and to display operational information; and
a cabinet, which encloses at least the pair of tanks.

US Pat. No. 10,791,705

AIR CUSHION DEVICE, SYSTEM AND METHOD FOR DETERMINING LAMENESS AND WEIGHT MONITORING

1. An air cushion device for determining lameness and total weight management in animals, the device comprising:a plurality of air cushions, each air cushion including a top member and a bottom member connected by an airtight seal between the top member and the bottom member along a perimeter of the air cushion, each air cushion further includes an expandable air pocket formed in the air cushion by the airtight seal, wherein each air cushion is configured to receive at least a portion of an animal on the top member, further wherein the expandable air pocket of each air cushion is connected to an incoming air line and a data air line;
a plurality of incoming air lines, each incoming air line connected to the expandable air pocket of one of the plurality of air cushions, wherein the incoming air lines supply each air cushion with a supply of air to inflate each air cushion; and
a plurality of data air lines, each data air line connected to the expandable air pocket of one of the plurality of air cushions, wherein the data air lines supply a force being exerted on each of the plurality of air cushions once the air cushions are inflated.

US Pat. No. 10,791,704

PET CARRYING BAG FOR INSTALLATION TO A BICYCLE HANDLE BAR

Xiamen Sunnypet Products ...

1. A pet carrying bag made of flexible material, comprising:a body having a rigid back board and a rigid bottom board embedded inside the flexible material;
two first tie bands extending from the right and left sides of the body, each of said first tie band further having a first fixed end and a first moving end, wherein a first insertion prong is formed at the distal tip of said first moving end;
two first insertion shells are formed on the right and left sides of the body, each of said first insertion shell is made to receive a first insertion prong;
at least one second tie band having two second moving ends, each of said second moving end further having a second insertion prong, wherein the second tie band has sufficient length to loop around a bicycle handle bar or a vertical turn rod of a bicycle;
two second insertion shells on the right and left sides of the back of the body, each of said second insertion shell is made to receive a second insertion prong;
a cling band is made on the back of the body for slidably receiving said at least one second tie band; and,
a support ring is made around the top edge of said body, propping up a top netting with a central opening the size of which can be controlled by a pull cord.

US Pat. No. 10,791,703

WALL ELEMENT FOR AN ANIMAL CAGE

BRUEGGLI, Romanshorn (CH...

1. An animal cage comprising:four extruded profiles on a cage wall which form a rectangle and include a horizontal extruded profile and an upright extruded profile;
a longitudinal groove on each of the tour extruded profiles;
and
a wall element for improving crash safety, which is rectangular, is fitted between the four extruded profiles and comprises side edges and at least one elastically compressible cavity configured to increase a crash safety of the animal cage,
wherein:
a) each of the side edges of the wall element forms a tongue of a tongue-and-groove connection with the longitudinal groove of a corresponding one of the four extruded profiles;
b) a metal insert is arranged at an end of the horizontal extruded profile for connection to the upright extruded profile;
c) the metal insert has three tines which project substantially parallel to one another from the metal insert;
d) a central tine of the three tines engages axially in a cavity of the horizontal extruded profile;
e) two outer tines of the three tines engage axially in two opposite longitudinal grooves of the horizontal extruded profile; and
f) the metal insert is connected to the upright extruded profile adjacent thereto.

US Pat. No. 10,791,702

PET WASTE COLLECTOR

1. A portable pet waste collector for protecting a horizontal floor surface and a vertical surface, comprising:a base collector comprising a first frame, a rigid base collecting tray, and a first pet waste collecting surface, the first pet waste collecting surface connected to the first frame, the first pet waste collecting surface is a first water absorbent surface, the rigid base collecting tray connected to the first frame, the rigid base collecting tray is located behind the first pet waste collecting surface;
a wall collector comprising a second frame, a rigid wall collecting tray, and a second pet waste collecting surface, the second pet waste collecting surface connected to the second frame, the second pet waste collecting surface is a second water absorbent surface, the rigid wall collecting tray connected to the second frame, the rigid wall collecting tray is located behind the second pet waste collecting surface;
a first hinge pivotally connecting the wall collector to the base collector, the wall collector is pivotal in a first direction relative to the base collector about the first hinge between a first closed position and a raised position where the second pet waste collecting surface is exposed to collect pet waste, the wall collector overlaps the base collector and covers the first pet waste collecting surface when in the first closed position;
a third collector comprising a third frame, a rigid third collecting tray, and a third pet waste collecting surface, the third pet waste collecting surface connected to the third frame, the third pet waste collecting surface is a third water absorbent surface, the rigid third collecting tray connected to the third frame, the third collecting tray is located behind the third pet waste collecting surface;
a second hinge, the second hinge pivotally connects the third collector to the base collector, the third collector is pivotal in a second direction relative to the base collector about the second hinge between a third collector closed position and a deployed position where the third pet waste collecting surface is exposed to collect pet waste, the third collector is horizontally adjacent to the base collector and horizontally oriented when in the deployed position, the third collector overlaps the base collector and the wall collector when the third collector is in the third collector closed position and the wall collector is in the first closed position, the third collector is horizontally offset from the wall collector when in the deployed position, the second hinge is transverse to the first hinge, the first direction is transverse to the second direction; and,
a releasable locking mechanism configured to releasably hold the wall collector in the raised position.

US Pat. No. 10,791,701

COLLAPSIBLE SOUND REDUCING PET CONTAINER

1. A pet container, comprising:top, bottom, front, rear, left, and right panels, the panels configured for assembly to form an enclosure having a fully assembled volume, the panels further configured to allow the assembled enclosure to be collapsed by detachment of the front, rear, left, and right panels from the top and bottom panels and by containment of the front, rear, left, and right panels within a fully collapsed volume defined only by the top and bottom panels;
a door formed through the front panel, the door configured to open to provide egress for the pet to and from the enclosure when the enclosure is fully assembled, and to close to enclose the pet within the enclosure when the enclosure is fully assembled, the door defining a cutout having an area less than half that of the front panel;
the cutout configured to prevent the pet from escaping the fully assembled enclosure through the cutout and to allow light and air to enter the fully assembled enclosure when the door is closed;
at least one of the panels comprising multiple layers of dissimilar soundproofing material;
an electric fan mounted to one of the panels;
an electric power source mounted to one of the panels;
a pressure switch configured to close under weight of the pet on the bottom panel; and
a door switch electrically coupled to the power source, to the pressure switch, and to the electric fan and configured to close in response to closure of the door and to thereby energize the fan only when the door is closed and when the weight of the pet presses on the bottom panel.

US Pat. No. 10,791,700

MILKING DEVICE

LELY PATENT N.V., Maassl...

1. A milking device for performing milkings, comprising:at least one milking cup with a teat space and a pulsation space,
a pulsation system comprising the pulsation space and a pulsator, the pulsator connected by a pulsation line to the pulsation space of the milking cup, and the pulsator provided with:
a vacuum source for supplying a vacuum pressure suitable for pulsation of the pulsation space during milking,
a vacuum line between the vacuum source and the pulsation line, and provided with a first controllable valve,
an aeration line between the pulsation line and a source of higher pressure than said vacuum pressure, and provided with a second controllable valve, and
a pulsator control system for pulsation of the milking cup, and configured for controlling the first and second valves with a pulsation period and configured to control a flushing mode for flushing the pulsation system to remove dirt, and/or measure pressure drops in the milking device, and/or measure air flow in the milking device, the flushing mode comprising simultaneously holding open the first and second valves during at least a predefined flushing time which is at least as long as the pulsation period.

US Pat. No. 10,791,688

NET CUP HOLDER FOR USE WITH HYDROPONIC VERTICAL TOWERS

1. A net cup holder for use with a hydroponic vertical tower system, the net cup holder comprising:a support portion, wherein the support portion is sized and configured to angularly retain a net cup therein;
a mounting flange at least partially surrounding the support portion, wherein the mounting flange is configured to provide one or more mounting points for the net cup holder to be mounted to an exterior surface of a vertical tower; and
a hole interface portion, wherein the hole interface portion is sized and configured to be inset within a hole formed within the vertical tower such that an interior face of the hole interface portion is flush with an interior surface of the vertical tower.

US Pat. No. 10,791,687

HYDROPONIC PLANT CULTIVATING APPARATUS

TOWER GARDEN, LLC, Colli...

1. A hydroponic plant cultivation apparatus comprising:a reservoir for holding fluid;
a plurality of rollers, the reservoir positioned on the plurality of rollers;
a plurality of planting modules stacked atop one another in an end to end configuration above the reservoir, each module including a sidewall, a hollow interior, at least one planting port defined in the sidewall for receiving a plant at least partially into the hollow interior, an open top end, a bottom wall configured to releasably engage the open top end, a plurality of drain holes defined in the bottom wall, at least one protrusion extending from the bottom wall directly below the at least one planting port, the at least one protrusion of each module above the lowermost module in the stack engaging the at least one planting port of an underlying adjacent module to prevent relative rotation between adjacent modules and vertically align the at least one planting port of each module of the plurality, and a module conduit extending from the bottom wall to the open top end, each module conduit in fluid communication with the module conduit of each adjacent module to form a planting column conduit in fluid communication with the reservoir; and
a fluid distributor positioned atop the plurality of planting modules, the fluid distributor in fluid communication with the planting column conduit;
wherein fluid is selectively circulated from the reservoir through the planting column conduit to the fluid distributor, where the fluid is redirected down the hollow interior of each planting module and back to the reservoir.

US Pat. No. 10,791,686

HYDROPONIC CULTIVATION UNIT AND SYSTEM

FUJIAN SANAN SINO-SCIENCE...

1. A hydroponic cultivation system for cultivating plants in a continuously flowing culture solution, comprising:a plurality of hydroponic cultivation units, each configured to provide a cultivation bed for the plants, wherein:
the plurality of hydroponic cultivation units are vertically stacked one over another to thereby form a multi-level structure; and
every two neighboring hydroponic cultivation units are hydrologically coupled to one another such that the culture solution flows top-to-bottom through each of the plurality of hydroponic cultivation units on each level;
and
a plurality of support members, disposed between, and are configured to provide mechanical support for, two hydroponic cultivation units on every two neighboring levels, wherein:
the plurality of support members comprise at least one pipe, each configured to arrange at least one of a hydrological connection or an electrical coupling between the two hydroponic cultivation units on the every two neighboring levels therein;
wherein each of the plurality of hydroponic cultivation units comprises a tank, wherein the tank comprises:
at least one separation bar, disposed on a bottom side of the tank and configured to separate the tank into a plurality of trough regions; and
at least one removable dam member, configured to be removably mounted in the tank to thereby block the culture solution from flowing therethrough;
wherein:
the at least one separation bar and the at least one removable dam member are configured to allow a configurable passageway for the culture solution flowing in the tank.

US Pat. No. 10,791,685

HYDROPONIC CULTIVATION UNIT AND SYSTEM

FUJIAN SANAN SINO-SCIENCE...

1. A hydroponic cultivation system for cultivating plants in a continuously flowing culture solution, comprising a plurality of hydroponic cultivation units, each configured to provide a cultivation bed for the plants, wherein:the plurality of hydroponic cultivation units are vertically stacked one over another to thereby form a multi-level structure; and
every two neighboring hydroponic cultivation units are hydrologically coupled to one another such that the culture solution flows top-to-bottom through each of the plurality of hydroponic cultivation units on each level;
wherein each of the plurality of hydroponic cultivation units comprises a tank, wherein the tank comprises:
at least one separation bar, disposed on a bottom side of the tank and configured to separate the tank into a plurality of trough regions; and
at least one removable dam member, configured to be removably mounted in the tank to thereby block the culture solution from flowing therethrough;
wherein:
the at least one separation bar and the at least one removable dam member are configured to allow a configurable passageway for the culture solution flowing in the tank.

US Pat. No. 10,791,684

INTELLIGENT GARDENING SYSTEM AND EXTERNAL DEVICE COMMUNICATING THEREWITH

POSITEC POWER TOOLS (SUZH...

1. An intelligent gardening system, for monitoring and controlling gardening apparatuses in a gardening area, comprising:multiple sensors that collect environmental information of the gardening area;
multiple gardening apparatuses that perform gardening work according to a control instruction;
a self-moving device that is capable of autonomously moving in the gardening area; and
a control center that generates the control instruction based on the environmental information; wherein the sensors, the gardening apparatuses and the control center communicate with each other to form an Internet of Things;
wherein the intelligent gardening system comprises multiple operating modes that comprise a party mode, a security mode, a vacation mode and a home mode, the control center configures operating statuses of the sensors and the gardening apparatuses according to one of the modes in response to a user instruction, wherein:
in the party mode, the intelligent gardening system configures operating parameters suitable for holding a party in the gardening area and multiple gardening apparatuses leave or stop operating in personnel activity areas in the gardening area;
in the security mode, the intelligent gardening system configures operating parameters suitable for users' leaving home and the gardening apparatuses perform security work;
in the vacation mode, the intelligent gardening system configures operating parameters suitable for users' leaving home for several days and some facilities in the gardening area are turned off; and
in the home mode, the intelligent gardening system configures operating parameters suitable for users' being at home and the intelligent gardening system adjusts operating parameters of the gardening apparatuses to reduce operating noise;
wherein the intelligent gardening system communicates with an external device, and sends data generated in the operation to the external device, and the external device comprises at least one of a manufacturer device, a service provider device, a distributor device, and a designer device.

US Pat. No. 10,791,683

IRRIGATION UNIT STABILIZER

1. A center pivot irrigation unit for rotating about a center and for irrigating a circular area in a field, the center pivot irrigation unit comprising:(a) a center tower having a vertical water line;
(b) a pivoting, horizontal, linear, elevated water line communicating with the vertical water line and extending therefrom;
(c) a plurality of spaced apart sprinkler lines communicating with the pivoting, horizontal, linear, elevated water line;
(d) a plurality of spaced apart, powered, A-frame towers on a plurality of wheels having lower surfaces supporting and rotating the pivoting, horizontal, linear, elevated water line about the center tower in a forward direction, the plurality of wheels contacting the field along a plane defined by a bottom of the plurality of wheels; and
(e) a pair of stabilizers on at least one tower of the plurality of spaced apart, powered, A-frame towers, one of the pair of stabilizers extending in the forward direction from the at least one tower and one of the pair of stabilizers extending in a rearward direction from the at least one tower, each stabilizer of the pair of stabilizers comprising an extension with no moving parts, wherein the extension having an angled portion extending toward the field and having a distal end that is suspended above a horizontal plane defined by the lower surfaces of the plurality of wheels a distance of two to twenty-four inches so the pair of stabilizers do not contact the field unless the center pivot irrigation unit begins to tip when exposed to an elevated transverse wind and so the pair of stabilizers do not affect performance of the center pivot irrigation unit unless the center pivot irrigation unit begins to tip, wherein the distal end of the angled portion of the extension of each said stabilizer of the pair of stabilizers contains a plate.

US Pat. No. 10,791,682

VEGETATION CUTTING AND CLEARING SYSTEM AND METHOD

1. A vegetation clearing device for clearing small diameter vegetation, the vegetation clearing device comprising:a grapple configured to releasably grapple the small diameter vegetation;
the grapple comprising a pair of left jaws and a pair of right jaws, each jaw adapted to transition between an open position and a closed position, wherein the pairs of jaws are adapted to cooperatively enclose around the small diameter vegetation in the closed position;
wherein the left pair of jaws rotate about a left pivot point and the right pair of jaws rotate about a right pivot point;
wherein the pair of left jaws and a pair of right jaws are operably connected via a link shaft that is aligned with the left and right pivot points, respectively;
a support frame configured to support the grapple and a cutter, wherein the support frame comprises a vegetation positioner, the vegetation positioner comprises a backing plate extending from the top to the bottom of the support frame and having a centrally located concave recess sized to partially receive the small diameter vegetation collected by the grapple wherein the concave recess extends entirely between a lower end and an upper end of the vegetation positioner;
wherein the cutter forms a lowermost position of the vegetation clearing device such that the cutter is configured to cut the small diameter vegetation engaged within the grapple in a shear position from a ground level such that a stub of no more than one-inch height extends from the ground level after cutting of the small diameter vegetation;
the cutter comprising a shear blade disposed at a first end thereof;
wherein the shear blade comprises a pilot point facing the concave recess in the shear position, wherein a pair of edges extend from adjacent sides of the pilot point;
wherein the cutter is coupled to a cutter link shaft at the second end thereof;
wherein the cutter is independently operable from the pair of jaws;
wherein a cutter actuator is operably connected to the cutter such that actuation thereof causes the cutter to transition between a retracted position and the shear position;
wherein a first end of the cutter actuator is mounted to the support frame and the second end operably connected to the cutter link shaft;
a pivot arm secured to the left pivot point at a first end and to the cutter link shaft at a second end, such that the second end of the cutter link shaft rotates about the left pivot point.

US Pat. No. 10,791,681

IDENTIFYING MANAGEMENT ZONES IN AGRICULTURAL FIELDS AND GENERATING PLANTING PLANS FOR THE ZONES

THE CLIMATE CORPORATION, ...

1. A method comprising:causing display, in a graphical user interface displayed on a display device, of digital planting plan data and a graphical element;
wherein the digital planting plan data comprises seeding rate data for an agricultural field;
wherein the graphical element comprises a feature that is adjustable by an input interaction with the graphical user interface;
in response to an adjustment of the feature of the graphical element, adjusting a relative importance ratio of two different data models that generate different types of planting plan recommendations, and causing display, in the graphical user interface, of adjusted seeding rate data;
wherein the adjusted seeding rate data is computed by applying a weight to the seeding rate data;
wherein the weight used to compute the adjusted seeding rate data is modified in correlation with the adjustment of the feature;
wherein the method is performed by one or more computing devices.

US Pat. No. 10,791,680

NETTING, CROP COVER, AND GROUND COVER MATERIALS

NINE IP LIMITED, Rosedal...

1. A crop netting material which is knitted, woven, or non-woven, from a synthetic monofilament, multifilament yarn, or tape or combination thereof, formed from a resin comprising at least one pigment such that the monofilament, multifilament yarn, or tape:across a UV wavelength range about 300 to about 380 nm:
absorbs at least about 55% solar radiation on average, and
transmits less than about 30% solar radiation on average;
across a visible wavelength range about 420 to about 700 nm:
transmits at least about 10% solar radiation on average, and
reflects at least about 10% of solar radiation on average;
across an infrared wavelength range about 700 to about 1000 nm: transmits between about 15% and about 80% of solar radiation on average;
across an infrared wavelength range of 1500 to 1600 nm: transmits at least about 15% to about 90% solar radiation on average; and
across an infrared wavelength range about 700 to about 1000 nm:
transmits not more than about 9 percentage points on average more than, and
transmits not less than about 9 percentage points on average less than,
the solar radiation transmission across said visible wavelength range about 420 to about 700 nm; and
across an infrared wavelength range about 1500 to about 1600 nm:
transmits not more than about 9 percentage points on average more than, and
transmits not less than about 9 percentage points on average less than,
the solar radiation transmission across said infrared wavelength range about 700 to about 1000 nm;
wherein the netting material has a cover factor of less than 80%;
wherein said pigment comprises titanium dioxide having an average particle size greater than 0.5 ?m; and
wherein said titanium dioxide comprises titanium dioxide coated with a coating comprising silica, alumina, or a combination thereof.

US Pat. No. 10,791,679

VERTICAL GROWING TOWER FOR AUTOMATED HORTICULTURE AND AGRICULTURE

Affinor Growers Inc., Va...

1. Apparatus for continuous automated growing of plants, comprising:a) a vertically extending central support element having a central vertical axis;
b) a hollow column mounted on said support element and rotatable about said central axis of said support element;
c) a plurality of vertically spaced, generally horizontal, generally co-planar arrays of plant supporting arms extending radially from said hollow column wherein each plant supporting arm is provided with an upwardly opening trough element to receive a plant seed, seedling or growing plant in a plant growth medium;
d) a plurality of liquid supply lines communicating with each trough element and supplied by a liquid feed line to provide water and liquid nutrient to each said trough element; and
e) a motor for rotating said hollow column about said central axis of said support means thereby rotating said plant supporting arms about said central axis of said support means;
wherein the interior of each said trough element communicates with the hollow column whereby liquid flows from each said trough element through related plant supporting arm which supports said each said trough element and into said hollow column.

US Pat. No. 10,791,678

MOVABLE FEED FLOOR FOR A COTTON HARVESTER

1. A cotton harvester including a cotton accumulator configured to accumulate cotton removed from cotton plants, the cotton harvester comprising:a feeder system configured to move independently of the cotton accumulator and along a longitudinal direction, wherein the feeder system includes a cam follower; and
a wrap floor configured to move along the longitudinal direction toward the feeder system, wherein the wrap floor includes a contact member adapted to contact the feeder system to establish a working gap between the feeder system and the wrap floor, and wherein the wrap floor includes a cam,
wherein movement of the wrap floor toward the feeder system moves the cam into contact with the cam follower to determine a dimension of an adjustable gap disposed between the feeder system and the wrap floor.

US Pat. No. 10,791,677

RETURN PAN FOR AN AGRICULTURAL COMBINE

1. A return pan for an agricultural combine for harvesting crops in an agricultural field and having a direction of travel through the field, wherein the return pan comprises:a textured floor configured to push grain toward an exit of the return pan when the return pan is oscillated in a fore-and-aft direction;
a first auger and a second auger that extend across a forward edge of the textured floor generally perpendicular to the fore-and-aft direction;
a first motor coupled to the first auger to drive the first auger in rotation; and
a second motor coupled to the second auger to drive the second auger in rotation;
wherein the first auger and the second auger are arranged to be selectively driven in opposite rotational directions and to be selectively driven in the same rotational direction.

US Pat. No. 10,791,676

MODULAR COMBINE TRACTION AXLE

CNH Industrial America LL...

1. A combine harvester comprising:a front axle assembly including a first tube, a second tube parallel to the first tube, and at least one bracket connecting the first tube and the second tube;
at least two wheels connected to the front axle assembly;
a cleaning system comprising:
a cleaning shoe; and
a fan mounted to the front axle assembly and positioned at least partially between the first tube and the second tube, the fan being configured for delivering air into the cleaning shoe; and
a transmission mounted to the at least one bracket for powering the at least two wheels, the transmission being positioned at least partially between the tubes.

US Pat. No. 10,791,675

COMBINE SYSTEM

1. An apparatus for transferring grain from combine storage to a secondary storage, the apparatus comprising:a first storage for placement of the grain;
a housing for transferring the grain to the secondary storage, the housing secured to the first storage;
a conveyor secured within the housing;
at least one paddle extending perpendicular from the conveyor;
an intake opening of the housing wherein the intake opening accepts grain into the housing, the intake opening located within the first storage;
an exit opening of the housing wherein the grain exits the housing at the exit opening; and
the paddle transferring grain from the intake opening to the exit opening;
a sidewall of the first storage wherein the sidewall is separate from the housing, the sidewall located laterally outward from the housing;
a pivot securing both the first storage and the housing to the combine, the pivot securing the housing interior of the sidewall of the first storage, the first storage and the housing rotatable in relation to the combine wherein the pivot secures the intake opening within the first storage.

US Pat. No. 10,791,674

MOWER SPRAYER ATTACHMENT APPARATUS

1. A mower sprayer attachment apparatus comprising:a tank mount, the tank mount comprising a plurality of support arms and a platform, the plurality of support arms being configured to couple to a deck of a mower, the platform being coupled to the plurality of support arms, the plurality of support arms of the tank mount comprising a pair of angled rear arms and a pair of vertical front arms;
a storage tank coupled to the tank mount, the storage tank having a fill aperture and a release aperture;
a fill cap coupled to the storage tank, the fill cap covering and alternatively uncovering the fill aperture;
an intake hose coupled to the storage tank, the intake hose being coupled to the release aperture;
a pump coupled to the deck of the mower, the pump having an intake port, a discharge port, and a drive wheel, the intake port being coupled to the intake hose, the drive wheel powering the pump to draw a liquid from the storage tank through the intake hose and intake port, pressurize said liquid and expel it through the discharge port;
a belt coupled to the pump, the belt being coupled to the drive wheel, the belt being configured to couple to a drive shaft of the mower, the drive shaft thus rotating the drive wheel; and
a spray apparatus coupled to the pump, the spray apparatus being coupled to the discharge port and releasing the liquid on each side of the mower.

US Pat. No. 10,791,673

DRIVE SYSTEM HAVING HYDRAULIC POWER TRANSMISSION FOR A HARVESTING HEADER OF A HARVESTER

1. A drive system for a harvesting header of a harvester, comprising:a drive motor, and
a drive train connected between the drive motor and a driven element of the harvesting header, the drive train having a variable-displacement hydraulic pump arranged on board the harvester and either a harvester-side hydraulic motor or a header-side hydraulic motor connected in a closed circuit to the hydraulic pump;
wherein the harvesting header includes a code readable by a control unit of the harvester,
the control unit is operable to open a valve arranged between the hydraulic pump and the header-side hydraulic motor if it is recognizable on the basis of information associated with the code that the harvesting header includes the header-side hydraulic motor mounted on the harvester header and detachably connect by coupling connections to the hydraulic pump for driving the harvesting header; and
the control unit is operable to open a valve arranged between the hydraulic pump and the harvester-side hydraulic motor if it is recognizable on the basis of information associated with the code that the harvesting header is not equipped with the header-side hydraulic motor for driving the harvesting header.

US Pat. No. 10,791,672

LAWN MOWER INCLUDING AN OPERATOR CONTROLLED DISCHARGE BAFFLE

Ariens Company, Brillion...

1. A lawn mower comprising:a frame;
a prime mover supported by the frame;
a plurality of ground engagement elements moveably coupled to the frame and driven by the prime mover to propel the lawn mower;
a cutting deck pan supported by the frame, the cutting deck pan defining an opening;
a cutting blade mounted below the cutting deck pan to cut vegetation under the cutting deck pan; and
a discharge baffle assembly coupled to the cutting deck pan adjacent the opening, the discharge baffle assembly including
a discharge chute extending outwardly from the cutting deck pan, the discharge chute defining a passageway configured to direct cut vegetation out from the opening of the cutting deck pan,
a baffle plate movable within a gap between the discharge chute and the cutting deck pan, the baffle plate being movable between a first position, in which the baffle plate substantially covers the opening of the cutting deck pan, and a second position, in which the baffle plate is spaced apart from the opening of the cutting deck pan, and
an actuator coupled to the baffle plate, the actuator operable to move the baffle plate relative to the opening of the cutting deck pan;
wherein the baffle plate includes a first section positioned on top of the cutting deck pan and a second section positioned within the gap, wherein the first section has a first edge pivotably coupled with respect to the cutting deck pan and a second edge opposite the first edge, wherein the second section has an edge pivotably coupled to the second edge of the first section, and wherein the actuator is coupled to the baffle plate adjacent the second edge of the first section and the edge of the second section to move the second section within the gap.

US Pat. No. 10,791,671

HEADER WITH FLEXIBLE CROP CUTTING KNIFE MOUNTED ON FLEX BLADES

MacDon Industries Inc., ...

1. A crop harvesting header comprising:a frame extending across a width of the header for movement in a forward direction generally at right angles to the width across ground including a crop to be harvested;
a mounting assembly for carrying the frame on a propulsion vehicle for up and down movement relative to the vehicle;
a cutter bar arranged to move over the ground in a cutting action and carrying a sickle knife operable for cutting the crop as the header is moved forwardly across the ground;
a draper transport system for moving the cut crop toward a discharge location of the header including at least one draper mounted on rollers generally parallel to the forward direction so that the draper carries the crop transverse to the forward direction, the draper having a front edge adjacent the cutter bar and a rear edge adjacent a rear of the frame;
the cutter bar being mounted on the frame at spaced positions along the length of the frame by elongate mounting components each connected at a rear end to a rigid beam of the frame and extending forwardly from the rigid beam to a front end connected to the cutter bar and which allow up and down flexing movement of the cutter bar relative to the frame;
wherein the rigid beam of the frame extends longitudinally of the frame parallel to and rearwardly of the cutter bar and is located forwardly of the rear edge of the draper;
wherein the frame includes a center section at the discharge location of the header at which is located a fore and aft draper for carrying the cut crop rearwardly from the cutter bar to the discharge location;
the fore and aft draper including a front draper roller located at a position spaced rearwardly of the cutter bar;
wherein there is provided, at the center section, a center rigid support beam which extends longitudinally of the frame in front of the front draper roller;
and wherein there is provided at least one center elongate mounting component connected at a rear end to the center rigid support beam and extending forwardly from the center rigid support beam to a front end connected to the cutter bar and which allows up and down flexing movement of the cutter bar relative to the frame in the center section.

US Pat. No. 10,791,670

DRIVE SYSTEM CONTROL FOR A MOBILE MACHINE

1. A mobile machine comprising:a first subsystem comprising propulsion components configured to propel the mobile machine;
a second subsystem;
a first drive mechanism;
a second drive mechanism;
a coupling mechanism movable between a first position in which the first drive mechanism is operably coupled to the second subsystem and a second position in which the second drive mechanism is operably coupled to the second subsystem; and
a controller configured to actuate the coupling mechanism to selectively couple one of the first or second drive mechanisms to drive one or more components of the second subsystem with variable speed and direction.

US Pat. No. 10,791,669

TURF VEHICLE HAVING ACCESSORY ATTACHMENT SYSTEM

THE TORO COMPANY, Bloomi...

1. A turf vehicle comprising:a chassis comprising front and rear sides and left and right sides;
a tool mounting panel located on each of the right side, left side, and rear side of the chassis, wherein each tool mounting panel defines a plurality of receivers; and
first and second tool connectors that each comprise:
a mounting portion adapted to be removably secured to the panels at two or more alternative locations via one or more of the plurality of receivers; and
a tool holding portion adapted to receive and hold an outdoor maintenance tool,
wherein the tool holding portion of the first tool connector is adapted to receive and support a first outdoor maintenance tool, and the tool holding portion of the second tool connector is adapted to receive and hold a second outdoor maintenance tool different than the first outdoor maintenance tool.

US Pat. No. 10,791,668

SEED METER DISK

1. A seed meter disk to be rotationally supported in an agricultural seed meter for metering seeds output to a soil furrow by a planter or air seeder, the seed meter disk comprising:a body defining a plane in which the seed meter disk rotates about a central axis perpendicular to the plane;
a circumferential array of seed openings to which seeds from a seed pool adhere in the presence of a pressure differential between a first side of the body on a first side of the plane and a second side of the body on a second side of the plane; and
a circumferential array of seed agitator pockets formed as depressions in the first side of the body, each one of the array of seed agitator pockets having a radially inner end, a radially outer end, and a trailing edge extending from the radially inner end to the radially outer end,
wherein at least a portion of the trailing edge of one or more of the seed agitator pockets among the array of seed agitator pockets is backswept so that a circumferential-direction offset from a radial reference line rotationally ahead of the trailing edge, with respect to rotation of the seed meter disk in an operational direction, increases toward the radially outer end,
wherein the backswept portion is non-linear, and wherein the non-linear backswept portion forms the entirety of the trailing edge.

US Pat. No. 10,791,666

AGRICULTURAL DATA ANALYSIS

THE CLIMATE CORPORATION, ...

1. A computer system for monitoring operations of one or more fields, comprising:a database for storing agricultural data including yield and field data related to the one or more fields; and
at least one processing unit coupled to the database, the at least one processing unit configured to:
monitor operations of the one or more fields,
store the agricultural data based on the monitoring,
automatically determine whether a correlation between the yield and a different variable or parameter of the agricultural data affecting the one or more fields exceeds a threshold, and
identify a category of issues that have potentially caused the correlation based on the agricultural data;
send a communication to a device including a recommendation to remedy the identified category of issues to be implemented by the device, to improve the yield for at least one field of the one or more fields.

US Pat. No. 10,791,665

TREE PLANTING SYSTEM, TREE PLANTING METHOD, CULTIVATING MACHINE, TREE PLANTING MACHINE, AND MANAGEMENT DEVICE

KOMATSU LTD., Tokyo (JP)...

1. A tree planting system comprising a first machine, a management device, and a second machine,the first machine including:
a cultivating device configured to cultivate soil where a plant for tree planting is to be planted;
a first traveling device configured to travel together with the cultivating device; and
a cultivated position detecting device configured to obtain by and output a plurality of actual cultivated positions which are positions corresponding to positions of the cultivating device while the cultivating device travels together with the first traveling device and cultivates the soil,
the management device storing the plurality of actual cultivated positions,
the second machine including:
a planting device configured to plant the plant in the soil cultivated by the cultivating device;
a second traveling device configured to travel together with the planting device;
a planting device position detecting device configured to obtain a position of the planting device; and
a control device configured to control a position of the planting device on the basis of the plurality of actual cultivated positions acquired from the management device and a position of the planting device obtained by the planting device position detecting device at a timing when the plant is planted.

US Pat. No. 10,791,664

WORK VEHICLE SUSPENSION HITCH

1. A hitch assembly for coupling a rotary cutter to a tractor, the hitch assembly comprising:a vehicle connection interface configured to attach the hitch assembly to the tractor, the vehicle connection interface disposed at a forward position;
a rotary cutter connection interface configured to attach the hitch assembly to the rotary cutter, the rotary cutter connection interface disposed at a rear position;
a mounting plate extending between the forward position and the rear position;
a pivot plate pivotally coupled to the mounting plate; and
a suspension element disposed between the mounting plate and the pivot plate to mitigate force transfer between the vehicle connection interface and the rotary cutter connection interface.

US Pat. No. 10,791,663

SOIL TREATMENT DEVICE

NOVOKRAFT AG, Itingen (C...

1. A ground treatment apparatus for ground with grass growth, the ground treatment apparatus comprising:a support device;
a plurality of injection elements held directly or indirectly on the support device;
a fluid providing device that is fluidically connected to the plurality of injection elements; and
at least one drive device adapted to lower and raise the plurality of injection elements in relation to the support device and to move the plurality of injection elements along a working direction of the ground treatment apparatus, wherein
the plurality of injection elements are inserted into the ground by being lowered in order to inject fluid into the ground in a treatment region, the plurality of injection elements remaining stationary during engagement in the ground in the treatment region, with relative movement in relation to the support device being moved in the working direction,
the plurality of injection elements are raised after an injection of fluid into the ground and are moved in the working direction in relation to the support device,
the plurality of injection elements, on being lowered again, are inserted into the ground in a further treatment region that is downstream of the first-mentioned treatment region, as seen in the working direction, and
the ground treatment apparatus comprises a holding device having a holding part on which the plurality of injection elements are held, the holding device being coupled to the support device by way of the at least one drive device, with the plurality of injection elements being raised and lowered in common as well as being moved along the working direction in common.

US Pat. No. 10,791,662

TWIN SHAFT GARDENING SYSTEM

1. A gardening system, comprising:a frame;
a first shaft mounted within the frame for rotation in a first direction;
a second shaft mounted within the frame for rotation in a second direction, which is opposite to the first direction;
a pair of wheels that rotate at a slower rate than the first shaft and the second shaft;
a drive system comprising a drive shaft, wherein the drive shaft is operably coupled to the first shaft, the second shaft, and the pair of wheels, wherein rotation of the drive shaft induces rotation of the first shaft, the second shaft, and the pair of wheels;
a first ground manipulation device attached to the first shaft, the first ground manipulation device having a planar section extending substantially perpendicular to the first shaft and an outer engaging edge having a plurality of irregularities; and
a second ground manipulation device attached to the second shaft, the second ground manipulation device having a planar section extending substantially perpendicular to the second shaft and an outer engaging edge having a plurality of irregularities.
US Pat. No. 10,792,348

ENHANCING T CELL ACTIVATION USING ALTERED MHC-PEPTIDE LIGANDS

Mayo Foundation for Medic...

1. A method comprising contacting a cell in a human with a virus particle comprising a nucleic acid sequence that encodes a variant of a wild-type human HLA-A0201 molecule consisting of a non-conservative amino acid substitution of G162 to tryptophan, tyrosine, or phenylalanine.
US Pat. No. 10,793,628

ISOLATED ANTIBODIES AGAINST INTERLEUKIN-17 RECEPTOR B (IL-17RB) FOR CANCER THERAPY

Academia Sinica, Taipei ...

1. An isolated antibody against interleukin-17 receptor B (IL-17RB), wherein the antibody comprises a heavy chain variable region (VH) comprising the VH CDR1-3 of SEQ ID NO:14-16, respectively; and a light chain variable region (VL) comprising the VL CDR1-3 of SEQ ID NO:17-19, respectively.
US Pat. No. 10,793,885

COMPOSITIONS AND METHODS FOR MAKING NOSCAPINE AND SYNTHESIS INTERMEDIATES THEREOF

Willow BioSciences Inc., ...

1. A method of making noscapine comprising:(a) providing a noscapine pathway precursor selected from a canadine derivative and a papaveroxine derivative; wherein
the canadine derivative is selected from the group of canadine derivatives consisting of each of (S)—N-methylcanadine; 1-hydroxy-N-methylcanadine; 1,13-dihydroxy-N-methylcanadine, 1-hydroxy-13-O-acetyl-N-methylcanadine; and 1,8-dihydroxy-13-O-acetyl-N-methyl canadine; and
the papaveroxine derivative is papaveroxine;
(b) contacting the noscapine pathway precursor with the enzymes listed below (i) in vitro or (ii) in a microorganism heterologously provided with the noscapine pathway precursor under reaction conditions permitting the catalysis of the noscapine pathway precursor to form noscapine;
wherein
(i) when the canadine derivative is (S)—N-methylcanadine, contacting the (S)—N-methylcanadine with each of the enzymes (i) CYP82Y1; (ii) CYP82X2; (iii) AT1; (iv) CYP82X1; (v) OMT; (vi) CXE1; and (vii) NOS;
(ii) when the canadine derivative is 1-hydroxy-N-methylcanadine, contacting the 1-hydroxy-N-methylcanadine with each of the enzymes (i) CYP82X2; (ii) AT1; (iii) CYP82X1; (iv) OMT; (v) CXE1; and (vi) NOS;
(iii) when the canadine derivative is 1,13-dihydroxy-N-methylcanadine, contacting the 1,13-dihydroxy-N-methylcanadine with each of the enzymes (i) AT1; (ii) CYP82X1; (iii) OMT; (iv) CXE1; and (v) NOS;
(iv) when the canadine derivative is 1-hydroxy-13-O-acetyl-N-methylcanadine, contacting the 1-hydroxy-13-O-acetyl-N-methylcanadine with each of the enzymes (i) CYP82X1; (ii) OMT; (iii) CXE1; and (iv) NOS;
(v) when the canadine derivative is 1,8-dihydroxy-13-O-acetyl-N-methylcanadine, contacting the 1,8-dihydroxy-13-O-acetyl-N-methylcanadine with each of the enzymes (i) OMT; and (ii) CXE1; and (iii) NOS;
(vi) when the papaveroxine derivative is papaveroxine, contacting the papaveroxine solely with the enzyme NOS; and
wherein
NOS comprises the amino acid sequence of SEQ.ID NO: 14; or a sequence at least 90% identical thereto;
CYP82Y1 comprises the amino acid sequence of SEQ.ID NO: 2, or a sequence at least 90% identical thereto;
CYP82X2 comprises the amino acid sequence of SEQ.ID NO: 4, or a sequence at least 90% identical thereto;
AT1 comprises the amino acid sequence of SEQ.ID NO: 6 or a sequence at least 90% identical thereto;
CYP82X1 comprises the amino acid sequence of SEQ.ID NO: 8, or a sequence at least 90% identical thereto;
OMT comprises the amino acid sequence of SEQ.ID NO: 10, or a sequence at least 90% identical thereto; and
CXE1 comprises the amino acid sequence of SEQ.ID NO: 12, or a sequence at least 90% identical thereto.
US Pat. No. 10,792,349

GALECTIN-3 AS IMMUNOLOGICAL TARGET

The Johns Hopkins Univers...

1. A method of inhibiting a pancreatic tumor in a patient comprising:(i) administering to the patient an allogeneic, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting pancreatic tumor cell vaccine, wherein the GM-CSF-secreting pancreatic tumor cell vaccine induces galectin-3 antibodies as compared to an unvaccinated control;
(ii) detecting a level of anti-galectin-3 antibodies in the serum of the patient induced by the GM-CSF-secreting pancreatic tumor cell vaccine, and
(iii) a) when the level of anti-galectin-3 antibodies in the serum of the patient induced by the GM-CSF-secreting pancreatic tumor cell vaccine declines, administering an anti-galectin 3 antibody to the patient to raise the level of anti-galectin-3 antibodies in the serum of the patient, or
b) administering an anti-galectin-3 antibody to the patient to maintain the level of anti-galectin-3 antibodies induced by the GM-CSF-secreting pancreatic tumor cell vaccine,thereby inhibiting a pancreatic tumor in the patient.
US Pat. No. 10,793,629

COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF

BOEHRINGER INGELHEIM INTE...

1. A nucleic acid encoding a compound comprising a first polypeptide and a second polypeptide, wherein:(A) said first polypeptide comprises:
(i) a light chain variable domain of a first immunoglobulin (VL1) specific for a first target protein;
(ii) a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second target protein; and
(iii) a hinge region, a heavy chain constant region 2 (CH2) and a heavy chain constant region 3 (CH3); and
(B) said second polypeptide comprises:
(i) a light chain variable domain of the second immunoglobulin (VL2) specific for said second target protein;
(ii) a heavy chain variable domain of the first immunoglobulin (VH1) specific for said first target protein;
(C) in said first and second polypeptides of (A) and (B):
(i) said VL1 and VH1 associate to form a binding site that binds said first target protein;
(ii) said VL2 and VH2 associate to form a binding site that binds said second target protein;
(iii) said heavy chain constant region 2 (CH2) is from a human IgG and comprises a tyrosine at position 252, a threonine at position 254 and a glutamic acid at position 256, numbered according to the EU index as in Kabat; and
(iv) said first target protein is Tumor Necrosis Factor-Alpha (TNF-alpha) and said second target protein is Interleukin-23A (IL-23A) or said first target protein is IL-23A and said second target protein is TNF-alpha,
and (D) in said first and second polypeptides of (A), (B), and (C):
(i) said VL1 comprises SEQ ID NO:2, said VH1 comprises SEQ ID NO:1, said VL2 comprises SEQ ID NO:8 and said VH2 comprises SEQ ID NO:7; or
(ii) said VL1 comprises SEQ ID NO:4 or 6, said VH1 comprises SEQ ID NO:3 or 5, said VL2 comprises SEQ ID NO:8 and said VH2 comprises SEQ ID NO:7; or
(iii) said VL1 comprises SEQ ID NO:8, said VH1 comprises SEQ ID NO:7, said VL2 comprises SEQ ID NO:2 and said VH2 comprises SEQ ID NO:1; or
(iv) said VL1 comprises SEQ ID NO:8, said VH1 comprises SEQ ID NO:7, said VL2 comprises SEQ ID NO:4 or 6 and said VH2 comprises SEQ ID NO:3 or 5.
US Pat. No. 10,793,886

METHOD FOR CONVERTING XYLOSE INTO XYLULOSE

METGEN OY, Kaarina (FI)

1. A method of converting xylose into xylulose, the method comprising:providing a composition comprising water, xylose and at least 0.06 grams per liter lignin, and
enzymatically converting the xylose in the composition to xylulose with a xylose isomerase,
wherein the xylose isomerase comprises an amino acid sequence having at least 95% identity with SEQ ID NO: 1 or SEQ ID NO: 2; and
wherein the xylose isomerase is in fluid contact with the lignin.
US Pat. No. 10,794,911

RELIABLE, COMPREHENSIVE, AND RAPID SEXUAL HEALTH ASSESSMENT

SIMPLE HEALTHKIT, INC., ...

1. A system for detection of a sexually transmitted infection, the system comprising:a sampling kit comprising:
a sample collecting tool for collecting a biological sample;
a container for receiving the sample collecting tool;
a buffer for being held within the container and for extracting, from the sample on the sample collecting tool, a target material associated with the sexually transmitted infection, the target material comprising a biomarker of a pathogen that causes the sexually transmitted infection, wherein the buffer comprises one or more of: phosphate buffered saline, Tris-buffered saline, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered saline, and an extraction substance comprising one or more of: 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate, a protein extraction reagent, octylthioglucoside, sodium hydroxide, Triton X-100, and octyl glucoside;
a signal output device, wherein the signal output device comprises:
a loading zone at a proximal end of the signal output device, the loading zone insertable into the container such that the loading zone receives the target material extracted in the buffer upon insertion of the loading zone into the container,
a reaction zone in fluid communication with the loading zone such that the received target material is able to pass from the loading zone to the reaction zone, the reaction zone comprising a first reaction substance conjugated to a first label, wherein the first reaction substance is capable of preferentially coupling to a first target of the received target material,
a testing zone in fluid communication with the reaction zone such that the first reaction substance and the first target material are able to pass from the reaction zone to the testing zone, the testing zone comprising a first testing substance retained at a first region of the testing zone, wherein the first testing substance is capable of preferentially coupling to the first target of the received target material such that the testing zone is able to visually display an indication of the detection of the sexually transmitted infection when the sexually transmitted infection is present; and
a control zone in fluid communication with the reaction zone such that the first reaction substance and the first target are able to pass through the testing zone to the control zone, the control zone comprising a control substance retained at the control zone, wherein the control substance is not capable of preferentially coupling to the target material;
wherein the sexual transmitted infection is an infection associated with at least one of: Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis; and
wherein the first reaction substance and the first testing substance each comprise at least one of the following aptamers: SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, or SEQ ID NO 16, or at least one of the following antibodies: M4020310, M2103128, M61872, M61871, M4020311, HM215, HM031, 9L102, B351M, CL13-256.2.1, CT 6703 SP-5, CT 6701 SP-5, CT 6709 SP-5, CL21-335.2.3, 027-10347, M2110186, M1709NG1, M1709NG2, 386/418, M86954, 20-NR08, 15B441, 17E95, M1011403, A19G, Q65G, BDI675, B985M, B986M, 15B485, 12K238, M1011401, M1011404, or 15B483.
US Pat. No. 10,792,350

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS

Immatics Biotechnologies ...

1. A method of treating cancer in a HLA-A*02+ patient, wherein said cancer comprises cancer cells that overexpress a AHNAK2 polypeptide and present at their surface in complex with an MHC class I molecule a peptide consisting of the amino acid sequence of SVDVSPPKV (SEQ ID NO: 4), said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to kill cancer cells, wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting in vitro CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface in complex with an MHC class I molecule a peptide consisting of the amino acid sequence of SVDVSPPKV (SEQ ID NO: 4), wherein said cancer is selected from pancreatic cancer, lung cancer, kidney cancer, melanoma, and esophageal cancer.
US Pat. No. 10,793,630

ANTI-CD38 ANTIBODIES FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

JANSSEN BIOTECH, INC., H...

1. A method of treating a subject having relapsed or refractory acute myeloid leukemia (AML), comprising administering to the subject in need thereof an anti-CD38 antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5 for a time sufficient to treat relapsed or refractory AML, wherein the subject has been treated with idarubicin, cytarabine or hydroxyurea, wherein the AML is AML with at least one mutation in a gene selected from the group consisting of fins-related tyrosine kinase 3 (FLT3), nucleophosmin (NPM1), isocitrate dehydrogenase 2 (IDH2), DNA (cytosine-5) methyltransferase 3 (DNMT3A) and CCAAT/enhancer binding protein alpha (CEBPA).
US Pat. No. 10,793,887

PROCESS FOR SACCHARIFYING CELLULOSIC MATERIAL UNDER OXYGEN ADDITION

1. A method of saccharifying a cellulosic material comprising subjecting the cellulosic material to a cellulolytic enzyme composition and a laccase in a vessel, wherein the cellulolytic enzyme composition comprises a family 61 glycoside hydrolase (GH61) polypeptide and wherein oxygen is added to the vessel to maintain a concentration of dissolved oxygen in the range of 11-90% of the saturation level, and maintained in the range of 11% to 75% of the saturation level, during at least 25% of the saccharification period, and, wherein the amount of laccase is in the range of 0.5% to 25% of total protein, and wherein the saccharified cellulosic material comprises increased sugars compared to a control saccharified without laccase, GH61 and oxygen addition.
US Pat. No. 10,794,912

IMMUNOADSORBENT FOR PURIFYING FIVE KINDS OF MYCOTOXINS INCLUDING FUMONISIN B1 AND AFLATOXIN B1, AND COMPLEX AFFINITY COLUMN

OILCROPS RESEARCH INSTITU...

1. An immunoadsorbent for purifying fumonisin B1, aflatoxin B1, ochratoxin A, zearalenone and sterigmatocystin, comprisinga solid-phase support; and
an anti-fumonisin B1 monoclonal antibody, an anti-aflatoxin B1 monoclonal antibody, an anti-ochratoxin A monoclonal antibody, an anti-zearalenone monoclonal antibody and an anti-sterigmatocystin monoclonal antibody, wherein each antibody is coupled to the solid-phase support,
wherein the anti-fumonisin B1 monoclonal antibody is secreted by a hybridoma cell strain Fm7A11, and the hybridoma cell strain Fm7A11 preserved in China Center for Type Culture Collection, Wuhan University, Wuhan, China on Mar. 29, 2016 with the deposit number CCTCC No. C201636.
US Pat. No. 10,792,351

COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTION

THE BOARD OF TRUSTEES OF ...

1. A vaccine vector comprising a first polynucleotide sequence encoding an Apicomplexan Rhomboid polypeptide expressed on the surface of the vaccine vector, wherein the Rhomboid polypeptide consists of a polypeptide having the amino acid sequence set forth in SEQ ID NO: 38 or an immunogenic fragment of SEQ ID NO: 38 comprising amino acids 1-11, 18-27, or 31-43 of SEQ ID NO: 38, and wherein the vaccine vector comprises a bacterial, yeast, viral or liposome-based vector.
US Pat. No. 10,793,888

IN VITRO METHOD FOR FAST SCARLESS DNA ASSEMBLY USING THERMOSTABLE EXONUCLEASES AND LIGASE

Jiangnan University, Wux...

1. A method for fast scarless in vitro DNA assembly, comprisinga) obtaining DNA subfragments with overlapping end sequences, wherein said DNA subfragments with overlapping end sequences are generated by polymerase chain reactions (PCR) that uses primers to add said overlapping end sequences to said DNA subfragments;
b) denaturing and annealing said DNA subfragments so that said DNA subfragments are annealed in an order according to their overlapping end sequences and unpaired single-stranded flap sequences are generated;
c) digesting said single-stranded flap sequences using thermostable DNA polymerases with 3?-5? and/or 5?-3? single-strand specific exonuclease activity, resulting in an assembled sequence with nicked gaps;
d) covalently sealing said nicked gaps using a thermostable ligase to form a scarless assembled sequence; and
e) optionally repeating steps b) to d) for more than one time.
US Pat. No. 10,792,352

METHOD FOR REDUCING SKATOLE AND/OR INDOLE IN ANIMALS

1. A method for reducing the concentration of skatole and/or indole in a first group of animals in a farm comprising: (i) evaluating whether at least one animal from a second group of animals in said farm has an infection with Lawsonia intracellularis or shows clinical signs associated with a Lawsonia intracellularis infection; and if said at least one animal from said second group of animals is confirmed to have an infection with Lawsonia intracellularis or shows clinical signs associated with a Lawsonia intracellularis infection, (ii) administering to said first group of animals an effective amount of an immunogenic composition comprising Lawsonia intracellularis antigen.
US Pat. No. 10,793,632

BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS

Xencor, Inc., Monrovia, ...

1. A heterodimeric anti-PD1 x anti-ICOS bispecific antibody comprising:a) a first monomer comprising, from N- to C-terminus, a scFv-linker-CH2-CH3 having the amino acid sequence of SEQ ID NO: 26362;
b) a second monomer comprising, from N- to C-terminus, a VH-CH1-hinge-CH2-CH3 having the amino acid sequence of SEQ ID NO: 26367; and
c) a third monomer comprising, from N- to C-terminus, a VL-CL having the amino acid sequence of SEQ ID NO: 26377, wherein scFv is an anti-PD1 scFv and VH and VL form an anti-ICOS binding domain.
US Pat. No. 10,793,889

METHOD OF PACKING POLYNUCLEOTIDES

KOREA INSTITUTE OF SCIENC...

1. A method of preparing nanoparticle polynucleotides, the method comprising forming the polynucleotides comprising modified nucleotides, wherein the forming comprises chemically synthesizing the polynucleotides comprising modified nucleotides, synthesizing the polynucleotides comprising modified nucleotides using an enzyme, or a combination thereof, and wherein the polynucleotides comprise at least partially a nucleotide sequence forming a secondary structure, a tertiary structure, a quaternary structure, or a combination thereof as a biomolecular structure, wherein the modified nucleotides have a modification of the hydrogen of the 8-carbon site of the purine ring when a base of the modified nucleotides is adenine or guanine, of the hydrogen of the 5-carbon site of the pyrimidine ring when a base of the modified nucleotides is cytosine or uracil, and of the methyl group of the 5-carbon site of the pyrimidine ring when a base of the modified nucleotides is thymine, the modified nucleotides being modified by substituting the hydrogen or the methyl group with a cationic residue.
US Pat. No. 10,797,219

PIEZOELECTRIC PTZT FILM, AND PROCESS FOR PRODUCING LIQUID COMPOSITION FOR FORMING SAID PIEZOELECTRIC FILM

MITSUBISHI MATERIALS CORP...

1. A piezoelectric PTZT film, formed of a metal oxide having a perovskite structure including Pb, Ta, Zr, and Ti,wherein the metal oxide further includes carbon, and a content of the carbon is 80 to 800 ppm by mass,
a fraction of Ta atoms with respect to total metal atoms of Zr atoms and Ti atoms is in a range of 0
US Pat. No. 10,792,353

VIRUS LIKE PARTICLE PURIFICATION

Takeda Vaccines, Inc., C...

1. A production method for Norovirus virus-like particles (VLPs), comprising:transforming insect cells with a baculovirus vector containing a viral nucleic acid sequence encoding a Norovirus major capsid protein VP1;
cultivating the insect cells in a medium thereby expressing the VLPs in the medium;
stopping cultivation when the viability of the insect cells reaches 20% or less; and
isolating supernatant comprising the VLPs from the insect cells thus producing the VLPs.
US Pat. No. 10,793,633

THERAPEUTIC PEPTIDES

Dana-Farber Cancer Instit...

1. A method of treating cancer in a subject, the method comprising administering a pharmaceutical composition comprising an antibody or antigen binding fragment thereof that binds to MHC class I polypeptide-related sequence A (MICA), wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) and wherein,(a) the VH complementarity determining region 1 (CDR1) consists of the amino acid sequence of SEQ ID NO: 153,
the VH CDR2 consists of the amino acid sequence of SEQ ID NO: 156,
the VH CDR3 consists of the amino acid sequence set forth in SEQ ID NO: 158;
the VL CDR1 consists of the amino acid sequence of SEQ ID NO:160,
the VL CDR2 consists of the amino acid sequence of SEQ ID NO: 162, and
the VL CDR3 consists of the amino acid sequence of SEQ ID NO: 164; or
(b) the VH CDR 1 consists of the amino acid sequence of SEQ ID NO:208,
the VH CDR2 consists of the amino acid sequence of SEQ ID NO:210,
the VH CDR3 consists of the amino acid sequence set forth in SEQ ID NO: 212,
the VL CDR1 consists of the amino acid sequence of SEQ ID NO:215,
the VL CDR2 consists of the amino acid sequence of SEQ ID NO:217, and
the VL CDR3 consists of the amino acid sequence of SEQ ID NO:219.
US Pat. No. 10,794,915

GENETICALLY ENCODED SENSORS FOR IMAGING PROTEINS AND THEIR COMPLEXES

THE REGENTS OF THE UNIVER...

1. A genetically encoded fluorescence protein fragment having a sequence that has a mass of less than 20 kDa, wherein the fragment has a sequence that is at least 95% identical to the sequence of SEQ ID NOS: 8 or 9 corresponding to the sequence of the genetically encoded fluorescence protein fragment, and having a fluorescent anisotropic lifetime that is >4.0 ns, wherein the genetically encoded fluorescence protein fragment further comprises an amino acid based targeting molecule, wherein the genetically encoded fluorescence protein fragment and the amino acid based targeting molecule are linked to each other by a linker, and wherein the genetically encoded fluorescence protein fragment is configured for fluorescent anisotropy-based measurement in a bound complex with a target protein.
US Pat. No. 10,793,634

ANTI-TRKB ANTIBODIES

Boehringer Ingelheim Inte...

1. An anti-TrkB antibody or an antigen-binding fragment thereof comprising:a. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48 (L-CDR1); the amino acid sequence of SEQ ID NO: 49 (L-CDR2); and the amino acid sequence of SEQ ID NO: 50 (L-CDR3); and
b. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51 (H-CDR1); the amino acid sequence of SEQ ID NO: 52 (H-CDR2); and the amino acid sequence of SEQ ID NO: 53 (H-CDR3), or
c. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 55 (H-CDR1); the amino acid sequence of SEQ ID NO: 56 (H-CDR2); and the amino acid sequence of SEQ ID NO: 57 (H-CDR3), or
d. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 58 (H-CDR1); the amino acid sequence of SEQ ID NO: 59 (H-CDR2); and the amino acid sequence of SEQ ID NO: 60 (H-CDR3).
US Pat. No. 10,794,916

METHODS OF GLYCOPROTEIN ANALYSIS

Momenta Pharmaceuticals, ...

1. A method of manufacture, comprising:producing a batch of test protein drug substance;
exposing a sample of the test protein in a first state to a stressor to obtain a labeled test protein in a second state, wherein the stressor comprises a first level of a first isobaric label that alters a higher-order structure of the test protein;
using mass spectrometry (MS) to obtain a test MS signal of the labeled test protein;
comparing the test MS signal to a target MS signal for a target protein drug product exposed to a first level of a second isobaric label, wherein the first level of the second isobaric label is the same as the first level of the first isobaric label, and wherein the target protein is approved under a primary approval process; and
processing the batch of the test protein drug substance as drug product if the test MS signal and the target MS signal are tolerable; or
taking an alternative action if the test MS signal and the target MS signal are not tolerable.
US Pat. No. 10,792,355

METHOD FOR PURIFYING AND CONCENTRATING INACTIVATED ANTIGEN OF FOOT-AND-MOUTH DISEASE VIRUS

JIANGSU ACADEMY OF AGRICU...

1. A method for purifying and concentrating inactivated foot-and-mouth disease virus, comprising the following steps of:(1) adding an adaptor protein with an amino acid sequence as shown in SEQ ID NO: 2 into the inactivated foot-and-mouth disease virus, mixing evenly, and incubating;
(2) adding a purified carrier, mixing evenly, and incubating the mixture, the purified carrier being a Lactococcus lactis skeleton;
(3) centrifuging and obtaining a precipitate.
US Pat. No. 10,793,635

THERAPEUTIC ANTIBODIES AND THEIR USES

PFIZER INC., New York, N...

1. A method of treating a condition associated with malignant cells expressing BCMA (B-Cell Maturation Antigen) in a subject comprising administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising a bispecific antibody comprising a first antibody variable domain capable of specifically binding to CD3, and a second antibody variable domain capable of specifically binding to BCMA, wherein the first antibody variable domain comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 320, 322, 324, 326, 328, 330, 345, 347, 349, 351, 444, 354, 356, 378, 442, 380, 382, 384 386, 388, 390, 392, 394, 396, 398, or 400; and a light chain variable (VL) region comprising a VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 319, 321, 323, 325, 327, 329, 344, 346, 348, 350, 352, 355, 377, 443, 445, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, or 399.
US Pat. No. 10,793,892

METHOD FOR DETECTING THE PRESENCE OF EXPANDED SPECTRUM ?-LACTAMASE-PRODUCING BACTERIA IN A SAMPLE

INSERM (INSTITUT NATIONAL...

1. A method for detecting the presence of expanded-spectrum ß-lactamase-producing bacteria in a blood or urine sample, said method comprising the steps of:a) performing cell lysis on the blood or urine sample in order to obtain an enzymatic suspension, wherein said bacteria in said blood or urine sample are not cultured to isolate said bacteria prior to step a);
b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising
an expanded-spectrum ß-lactamase (EBSL) substrate selected from cephalosporins and aztreonam; and,
a pH color indicator which will change color when the pH of the reaction mixture is from 6.4 and 8.4,
wherein a color change visually observed within 5 minutes to 120 minutes after the beginning of step b) indicates the presence of expanded-spectrum ß-lactamase-producing bacteria in the blood or urine sample.
US Pat. No. 10,794,917

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF APPENDICITIS AND DIFFERENTIATION OF CAUSES OF ABDOMINAL PAIN

Astute Medical, Inc., Sa...

1. A method of detecting C-C motif chemokine 4 in a subject who is being evaluated for appendicitis, the method comprising:a) performing an assay configured to detect C-C motif chemokine 4 on a body fluid sample obtained from the subject who is being evaluated for appendicitis to provide an assay result,
b) diagnosing the subject with appendicitis based on the assay result, and
c) treating the subject diagnosed with appendicitis by appendectomy.
US Pat. No. 10,792,356

RECOMBINANT RSV WITH SILENT MUTATIONS, VACCINES, AND METHODS RELATED THERETO

Emory University, Atlant...

1. An isolated recombinant nucleic acid comprising a NS1 gene of the RSV genome, wherein the NS1 gene has at least 90% sequence identity to SEQ ID NO: 6.
US Pat. No. 10,792,612

METHODS AND COMPOSITIONS FOR THE REMOVAL OF MERCURY FROM GASES

UNIVERSITY OF WYOMING, L...

1. A process for removal of contaminants in a fluid, said process comprising the steps of:contacting said contaminants in said fluid with a trihalide salt provided on an ash substrate or a fiber substrate;
wherein said trihalide salt comprises an oxidizing trihalide anion and cationic nitrogen counter ion;
wherein said trihalide anion has the formula [Br—Br—Br]?, [Br—Br—Cl]?, [Br—Br—I]?; or [Br—I—I]?; and
wherein the trihalide anion oxidizes said contaminants, thereby generating one or more reaction products resulting in removal of said contaminants in said fluid; and
wherein said substrate is a fiber substrate and fibers of said fiber substrate have a cross sectional dimension selected over the range of 0.1 ?m to 100 ?m.
US Pat. No. 10,793,636

ANTI-CD73 ANTIBODIES

CORVUS PHARMACEUTICALS, I...

1. An anti-CD73 antibody comprising(i) a light chain variable domain comprising a CDR L1 comprising the amino acid sequence of SEQ ID NO:1 modified by the replacement of the asparagine residue therein with an amino acid residue selected from glutamine, alanine and aspartic acid; a CDR L2 comprising the amino acid sequence of SEQ ID NO:2 and a CDR L3 comprising the amino acid sequence of SEQ ID NO:3;
(ii) a heavy chain variable domain comprising a CDR H1 comprising the amino acid sequence of SEQ ID NO:4, a CDR H2 comprising the amino acid sequence of SEQ ID NO:5 and a CDR H3 comprising the amino acid sequence of SEQ ID NO:6.
US Pat. No. 10,793,893

METHODS OF ADMINISTERING 3,4-DIAMINOPYRIDINE

SERB SA, Brussels (BE)

1. A method of treating a human patient diagnosed with a 3,4-diaminopyridine (3,4-DAP) sensitive disease in need of treatment thereof comprising administering a dose of about 2.5 mg to about 30 mg of 3,4-DAP or a pharmaceutically acceptable salt thereof to a human patient who is a slow acetylator having an N-acetyl transferase 2 (NAT2) gene comprising: a C282T mutation on both alleles of the NAT2 gene; a T341C mutation on both alleles of the NAT2 gene; or a C282T mutation on one allele of the NAT2 gene and a T341C mutation on the other allele of the NAT2 gene.
US Pat. No. 10,794,918

USE OF GFAP FOR IDENTIFICATION OF INTRACEREBRAL HEMORRHAGE

Matthias Sitzer, Herford...

1. A method of treating a stroke patient, the method comprising the steps of:detecting whether Glial Fibrillary Acidic Protein (GFAP) is present in a blood or serum sample obtained from the patient within six hours after onset of a stroke by contacting, in vitro, a portion of the blood or serum sample with a detection antibody having specific binding affinity for GFAP and detecting a complex formed between the detection antibody and GFAP; and
treating the patient with an intracerebral hemorrhage-specific therapy if the presence of GFAP is detected or treating the patient with an ischemic stroke-specific therapy if the presence of GFAP is not detected.
US Pat. No. 10,792,357

OPTIMIZED HIV ENVELOPE GENE AND EXPRESSION THEREOF

INTERNATIONAL AIDS VACCIN...

1. A viral vector containing and expressing a nucleic acid encoding a Clade A Env-F hybrid based on BG505, wherein the Env signal sequence (SS), transmembrane region (TMR), and the cytoplasmic tail (CT) of HIV-Env-F are replaced with an analogous sequence from the Sendai virus F gene.
US Pat. No. 10,792,869

PREFORM, FIBER-REINFORCED COMPOSITE MATERIAL, AND METHOD OF MANUFACTURING FIBER-REINFORCED COMPOSITE MATERIAL

Toray Industries, Inc., ...

1. A preform comprising a plurality of reinforcement fiber layers connected to each other by binder resin, the binder resin containing spacer particles insoluble in the binder resin, the spacer particles accounting for a volume proportion of 35% to 80% in the binder resin present in interlaminar gaps between the reinforcement fiber layers and a quantity of the binder resin present in the interlaminar gaps between reinforcement fiber layers is 0.5 to 50 g/m2;wherein the spacer particles are polymer particles having a glass transition temperature of 80° C. or more and comprise at least one resin compound selected from the group consisting of polyamide, polyamide-imide, polyimide, polycarbonate, polyphenylene sulfide, polyphenylene ether, polyether ether ketone, and copolymers thereof.
US Pat. No. 10,793,637

ANTIBODIES THAT BIND CD39 AND USES THEREOF

Surface Oncology, Inc., ...

1. A method of treating a cancer associated with CD39 expression in the tumor microenvironment, the method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated anti-CD39 antibody, wherein the isolated anti-CD39 antibody comprises:i. (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 27; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 28; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 37; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 38; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 39; or
ii. (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 30; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 31; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 32; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 40; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 41; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 42.
US Pat. No. 10,793,894

QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS FOR DETERMINING THE PRESENCE, IDENTITY, OR SEVERITY OF A DISEASE OR CONDITION

BIOMARIN PHARMACEUTICAL I...

1. A method of determining the presence, identity, and/or severity of a disease or condition in an individual, wherein the disease or condition is associated with abnormal glycan biosynthesis, degradation, or accumulation, the method comprising:(a) generating a biomarker comprising of one or more non-reducing end glycan residual compound(s), wherein the biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme(s), wherein prior to enzyme treatment, the biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition;
(b) detecting the presence of and/or measuring the amount of the biomarker produced using an analytical instrument and displaying or recording the presence of or the measure of the biomarker produced; and
(c) correlating the presence of and/or the measure of the amount of the biomarker with the presence, identity, and/or severity of the disease or condition for determining the presence, identity, and/or severity of the disease or condition in the individual,
wherein the disease or condition is a neurological disorder.
US Pat. No. 10,792,358

ISG15 AND ITS USE AS AN ADJUVANT

THE TRUSTEES OF THE UNIVE...

1. A vaccine comprising:a) an antigen, a nucleic acid molecule encoding an antigen, or a combination thereof; and
b) a nucleic acid molecule comprising a nucleotide sequence encoding ISG15, wherein the nucleotide sequence encoding ISG15 comprises one or more nucleotide sequences selected from the group consisting of a nucleotide sequence having at least about 95% identity to the nucleotide sequence as set forth in SEQ ID NO:5 and the nucleotide sequence as set forth in SEQ ID NO:5.
US Pat. No. 10,792,614

PROCESS AND APPARATUS FOR TREATMENT OF GAS STREAMS CONTAINING NITROGEN OXIDES

BASF SE, Ludwigshafen (D...

1. Process for the treatment of a gas stream containing nitrogen oxides comprising:(1) providing a gas stream comprising N2O and NOx;
(2) contacting the gas stream provided in step (1) with a transition metal containing zeolitic material having a BEA-type framework structure for the selective catalytic reduction of both N2O and NOx;
wherein the zeolitic material is obtained from an organotemplate-free synthetic process, wherein the gas stream provided in step (1) further comprises one or more reducing agents, wherein the reducing agent does not comprise ammonia or urea; wherein the stoichiometric ratio of the one or more reducing agents to the one or more nitrogen oxides is in the range of from 0.05 to 50;
wherein the one or more reducing agents comprise one or more hydrocarbons selected from the group consisting of C1 to C6 alkanes;
and wherein transition metal containing zeolitic material having a BEA-type framework structure is effective for converting greater than 45% of the N2O and greater than 98% of the NOx at temperatures less than 420° C.,
said organotemplate-free synthetic process comprising
(I) preparing a mixture comprising one or more sources for YO2, one or more sources for X2O3, and seed crystals comprising one or more zeolitic materials having a BEA-type framework structure;
(II) crystallizing the mixture obtained in step (I); wherein the mixture provided in step (I) and crystallized in step (II) does not contain an organotemplate as structure-directing agent; and
(IIIa) exchanging one or more of the ionic non-framework elements contained in the zeolitic material having a BEA-type framework structure obtained in step (II) against NH4+, and
(IIIb) calcining the zeolitic material having a BEA-type framework structure obtained in step (IIIa) to obtain the hydrogen from zeolite; and
(IIIc) exchanging one or more of the acidic hydrogens contained in the zeolitic material having a BEA-type framework structure obtained in (IIIb) against Fe, wherein the total amount of the Fe in the ion-exchanged material obtained in step (III) is comprised in the range of from 3 to 6 wt % calculated as Fe2O3 based on the total mass of the ion exchanged material,
wherein the nitrogen oxides are comprised in the gas stream to be treated in step (2) in an amount ranging from 1,150 ppmv to 15,000 ppmv.
US Pat. No. 10,793,638

USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER

Innovative Cellular Thera...

1. An isolated nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain binds to Guanylate cyclase 2C (GUCY2C), and wherein the CAR comprises amino acid sequence SEQ ID NO: 40.
US Pat. No. 10,793,895

SYSTEMS AND METHODS FOR EPIGENETIC ANALYSIS

Seven Bridges Genomics In...

1. A method for determining genomic modifications in a subject, the method comprising using at least one hardware processor connected to a tangible memory subsystem to perform:obtaining a first sequence of nucleotide bases from nucleic acid from a subject, the nucleic acid representative of the genome of the subject;
creating, in the tangible memory subsystem, a directed acyclic graph (DAG), the DAG comprising a plurality of vertices stored as objects in the tangible memory subsystem, wherein each object comprises a sequence substring and a list of one or more pointers identifying a physical location in the tangible memory subsystem at which an adjacent object is stored, each sequence substring representing a nucleotide sequence, wherein at least one sequence substring comprises a plurality of symbols;
wherein creating the DAG further comprises creating at least one path that splits into a first branch and a second branch, which first branch and second branch subsequently rejoin, wherein the first branch comprises a first vertex representing a cytosine base observed in a position of the first sequence and the second branch comprises a second vertex representing a thymine base not observed in the position, the first vertex and second vertex each further comprising a pointer to a memory address containing a third vertex comprising a sequence substring from the subject's genome;
obtaining a second sequence from bisulfite-treated nucleic acid from the subject;
aligning the second sequence to paths through the DAG, wherein the aligning comprises calculating match scores between the second sequence and each of the sequence substrings associated with the first, second, and third vertices, and looking backward at each vertex against the direction of the DAG to any prior vertices if and only if a symbol comprises the first symbol of the string associated with its vertex to select a path with a maximum score;
identifying—in the alignment of the second sequence to the DAG—a corresponding cytosine base in the second sequence that matches the cytosine base observed in the position of the first sequence; and
providing a report that identifies a methylated base at the position.
US Pat. No. 10,793,639

METHODS OF TREATING BY ADMINISTERING ANTI-KIT ANTIBODIES

Celldex Therapeutics, Inc...

1. A method for treating or managing a KIT-mediated disorder, wherein the KIT-mediated disorder is associated with KIT expression and/or activity, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or an antigen-binding fragment thereof, which immunospecifically binds to human KIT and comprises:(i) a variable light (“VL”) chain region comprising a VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, respectively; and
(ii) a variable heavy (“VH”) chain region comprising a VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively.
US Pat. No. 10,793,896

METHODS FOR RT-PCR COMPRISING AN ANIONIC POLYMER

QIAGEN GmbH, Hilden (DE)...

1. A method for the generation and amplification of nucleic acids by coupled reverse transcriptase-polymerase chain reaction, the method comprising steps of:(a) incubating a reaction mixture comprising (i) a RNA template, (ii) at least one reverse transcriptase, (iii) at least one nucleic acid polymerase, (iv) an anionic polymer that is not a nucleic acid and is selected from the group consisting of sodium alginate, sodium carboxymethylcellulose, polyphloretin phosphate, poly-L-glutamate, polyacrylic acid, poly(propylacrylic acid), and poly(methyl-vinyl-ether-maelic anhydride), and (v) one or more oligonucleotide primers at a temperature sufficient to synthesize a DNA molecule that is complementary to at least a portion of the RNA template; and
(b) thermocycling the reaction mixture from step (a) containing the DNA molecule to replicate the DNA molecule.
US Pat. No. 10,793,640

MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE

1. A nucleic acid, or a set of nucleic acids, encoding a heavy and light chain variable region of an antibody which binds to human epidermal growth factor receptor 2 (HER2), wherein the antibody comprises heavy and light chain variable regions selected from the group consisting of:a) SEQ ID NOs: 1 and 5, respectively;
b) SEQ ID NOs: 8 and 12, respectively;
c) SEQ ID NOs: 15 and 19, respectively;
d) SEQ ID NOs: 22 and 26, respectively;
e) SEQ ID NOs: 29 and 33, respectively;
f) SEQ ID NOs: 36 and 40, respectively;
g) SEQ ID NOs; 43 and 44, respectively;
h) SEQ ID NOs: 45 and 46, respectively;
i) SEQ ID NOs: 47 and 48, respectively;
j) SEQ ID NOs: 49 and 50, respectively;
k) SEQ ID NOs: 51 and 52, respectively;
l) SEQ ID NOs: 53 and 54, respectively; and
m) SEQ ID NOs: 55 and 56.
US Pat. No. 10,793,897

PRIMER AND PAYLOAD DESIGN FOR RETRIEVAL OF STORED POLYNUCLEOTIDES

Microsoft Technology Lice...

1. A system comprising:a processing unit;
a memory in communication with the processing unit, the memory storing computer-readable instructions that when executed by the processing unit perform operations comprising:
obtaining a primer target sequence that is complementary to a primer sequence;
comparing the primer target sequence to a payload sequence, the payload sequence encoding digital data;
determining that a region of the primer target sequence has more than a threshold similarity with a region of the payload sequence;
generating an alternate payload sequence, the alternate payload sequence encoding the same digital data; and
determining that the primer target sequence has less than the threshold amount of similarity with the alternate payload sequence.
US Pat. No. 10,792,361

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS

NOVARTIS AG, Basel (CH)

1. A compound, or a pharmaceutically acceptable salt thereof, selected from:1-(3,5-bis((Z)-octadec-9-en-1-yloxy)phenyl)-N,N-dimethylmethanamine;
1-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenyl)-N,N-dimethylmethanamine;
2,2?-((3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzl)azanediyl)diethanol;
1-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl)pyrrolidine;
1-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl)azetidin-3-ol;
ethyl 2-((3,5-bis((Z)-octadec-9-en-1-yloxy)benzyl)(methyl)amino)acetate;
1-(3,5-bis((Z)-octadec-9-en-1-yloxy)benzyl)pyrrolidine;
2-((3,5-bis((Z)-octadec-9-en-1-yloxy)benzyl)(methyl)amino)acetic acid
1-((2-(3,5-bis((Z)-octadec-9-en-1-yloxy)phenyl)-1,3-dioxolan-4-yl)methyl)pyrrolidine;
1-(2-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenyl)-1,3-dioxolan-4-yl)-N,N-dimethylmethanamine;
1-((2-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenyl)-1,3-dioxolan-4-yl)methyl)piperidine;
(2-(3,5-bis((Z)-octadec-9-en-1-yloxy)phenyl)-1,3-dioxolan-4-yl)methyl 2-(dimethylamino)acetate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl4-(dimethylamino)butanoate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl3-(dimethylamino)propanoate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl2-(dimethylamino)acetate;
4-methyl-3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl3-(dimethylamino)propanoate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl3-(dimethylamino)-2-methylpropanoate;
2-(dimethylamino)ethyl 2,6-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)isonicotinate;
3-(dimethylamino)propyl2,6-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)isonicotinate;
(9Z,9?Z,12Z,12?Z)-5-(((3-(dimethylamino)propanoyl)oxy)methyl)-1,3-phenylene bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-5-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,3-phenylene bis(octadeca-9,12-dienoate);
(2,6-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)pyridin-4-yl)methyl3-(diethylamino)propanoate;
(2,6-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)pyridin-4-yl)methyl 4-(dimethylamino)butanoate;
(2,6-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)pyridin-4-yl)methyl3-(dimethylamino)propanoate;
1-(2,6-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)pyridin-4-yl)-N,N-dimethylmethanamine;
di(9Z,12Z)-octadeca-9,12-dien-1-yl) 5-(((3-(dimethylamino)propanoyl)oxy)methyl)isophthalate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-ylcarbamoyl)benzyl 3-(dimethylamino)propanoate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-ylcarbamoyl)benzyl 4-(dimethylamino)butanoate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenethyl 3-(dimethylamino)propanoate;
3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl (3-(dimethylamino)propyl) carbonate;
(9Z,9?Z,12Z,127)-5-((((2-(dimethylamino)ethoxy)carbonyl)oxy)methyl)-1,3-phenylene bis(octadeca-9,12-dienoate;)
3-(dimethylamino)propyl 4-isopropyl-3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl carbonate;
4-bromo-3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl (3-(dimethylamino)propyl) carbonate;
4-chloro-3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl (3-(dimethylamino)propyl) carbonate;
N-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl)-2-(dimethylamino)acetamide;
3-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenyl)propyl 3-(dimethylamino)propanoate;
N,N-dimethyl-1-(3,4,5-tris((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenyl)methanamine;
2-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenyl)-N,N-dimethylethanamine;
3-(3,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenyl)-N,N-dimethylpropan-1-amine;
(9Z,9?Z,12Z,12?Z)-((5-(((3-(dimethylamino)propanol)oxy)methyl)-1,3-phenylene)bis(oxy))bis(ethane-2,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-(((3-(dimethylamino)propanoyl)oxy)methyl)-1,3-phenylene)bis(oxy))bis(propane-3,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-(2-(dimethylamino)acetoxy)methyl)-1,3-phenylene)bis(oxy))bis(propane-3,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-(2-(dimethylamino)acetoxy)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-(((3-(dimethylamino)propanoyl)oxy)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,3-phenylene)bis(oxy))bis(ethane-2,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(propane-3,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(ethane-2,1-diyl) bis(octadeca-9,12-dienoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl) dihexanoate;
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl) dioctanoate;
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(decane-10,1-diyl) dioctanoate;
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(decane-10,1-diyl) dihexanoate;
(9Z,9?Z,12Z,12?Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(hexane-6,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(octadeca-9,12-dienoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(hexane-6,1-diyl) bis(decanoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(hexane-6,1-diyl) dioctanoate;
(9Z,9?Z,12Z,12?Z)-((5-((3-hydroxyazetidin-1-yl)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
(8Z,8?Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(hexane-6,1-diyl) bis(dodec-8-enoate);
(9Z,9?Z,12Z,12?Z)-((5-((dimethylamino)methyl)-2-methyl-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl) didodecanoate;
(9Z,9?Z,12Z,12?Z)-((5-((diethylamino)methyl)-2-methyl-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(propane-3,1-diyl) bis(3-octylundecanoate);
didecyl 8,8?-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))dioctanoate;
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(hexane-6,1-diyl) didodecanoate;
(Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) dioleate;
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) ditetradecanoate;
(9Z,9?Z,12Z,12?Z,15Z,15?Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12,15-trienoate);
(9Z,12Z)-4-(3-((dimethylamino)methyl)-5-(4-(oleoyloxy)butoxy)phenoxy)butyl octadeca-9,12-dienoate;
(9Z,12Z,15Z)-4-(3-((dimethylamino)methyl)-5-(4-(9Z,12Z)-octadeca-9,12-dienoyloxy)butoxy)phenoxy)butyl octadeca-9,12,15-trienoate;
di((9Z,12Z)-octadeca-9,12-dien-1-yl) 5,5?-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))dipentanoate;
didodecyl 6,6?((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))dihexanoate;
(9Z,12Z)-3-(3-((dimethylamino)methyl)-5-(3-((3-octylundecanoyl)oxy)propoxy)phenoxy)propyl octadeca-9,12-dienoate;
((5-((dimethylamino)methyl)benzene-1,2,3-triyl)tris(oxy))tris(decane-10,1-diyl) trioctanoate;
((5-((diethylamino)methyl)benzene-1,2,3-triyl)tris(oxy))tris(decane-10,1-diyl) trioctanoate;
(9Z,12Z)-4-(3-((dimethylamino)methyl)-5-(4-((Z)-dodec-8-enoyloxy)butoxy)phenoxy)butyl octadeca-9,12-dienoate;
(9Z,12Z)-4-(3-((dimethylamino)methyl)-5-(4-((3-octylundecanoyl)oxy)butoxy)phenoxy)butyl octadeca-9,12-dienoate;
(9Z,9?Z,12Z,12?Z)-((5-(pyrrolidin-1-ylmethyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(7-hexyltridecanoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(9-pentyltetradecanoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(5-heptyldodecanoate);
((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(3-octylundecanoate);
(9Z,9?Z,12Z,12?Z)-((5-(3-(piperidin-1-yl)propyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-(3-(dimethylamino)propyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((5-(3-morpholinopropyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);
((5-(((3-(dimethylamino)propanoyl)oxy)methyl)-1,3-phenylene)bis (oxy))bis(octane-8, 1-diyl) bis(decanoate);
((5-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);
(9Z,9?Z,12Z,12?Z)-(5-(((3-(dimethylamino)propanoyl)oxy)methyl)-1,3-phenylene)bis(methylene) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(octadeca-9,12-dienoate);
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) ditridecanoate;
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(3-octylundecanoate);
(9Z,12Z)-3-((dimethylamino)methyl)-5-(((3-octylundecanoyl)oxy)methyl)benzyl octadeca-9,12-dienoate;
(9Z,9?Z,12Z,12?Z)-(5-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)-1,3-phenylene)bis(methylene) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-(5-((((2-(dimethylamino)ethoxy)carbonyl)oxy)methyl)-1,3-phenylene)bis(methylene) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-(5-((((3-(dimethylamino)propoxy)carbonyl)oxy)methyl)-1,3-phenylene)bis(methylene) bis(octadeca-9,12-dienoate);
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(5-heptyldodecanoate);
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(7-hexyltridecanoate);
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(9-pentyltetradecanoate);
O,O?-((5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene)) di((9Z,12Z)-octadeca-9,12-dien-l-yl) disuccinate;
O,O?-((5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene)) bis(10-(octanoyloxy)decyl) disuccinate;
O?1,O1-(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene)) 8-dinonyl dioctanedioate;
O?1,O1-(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene)) 9-dioctyl dinonanedioate;
(9Z,9?Z,12Z,12?Z)-(((5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(4-oxobutane-4,1-diyl) bis(octadeca-9,12-dienoate);
(((5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(8-oxooctane-8,1-diyl) bis(decanoate);
(((5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(4-oxobutane-4,1-diyl) dioctanoate;
(((5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(6-oxohexane-6,1-diyl) dioctanoate;
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(10-(octanoyloxy)decanoate);
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(8-(octanoyloxy)octanoate);
(((5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(6-oxohexane-6,1-diyl) bis(decanoate);
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(8-decanamidooctanoate); and
(5-((dimethylamino)methyl)-1,3-phenylene)bis(methylene) bis(6-(((nonyloxy)carbonyl)oxy)hexanoate);
(9Z,9?Z,12Z,12?Z)-((((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) bis(octadeca-9,12-dienoate);
(9Z,9?Z,12Z,12?Z)-((((5-((diethylamino)methyl)-1,3-phenylene)bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) bis(octadeca-9,12-dienoate);
((((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(propane-3,1-diyl))bis(oxy))bis(4-oxobutane-4,1-diyl) bis(decanoate);
O?1,O1-(((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(propane-3,1-diyl)) 9-dioctyl dinonanedioate;
4,4?-(5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-1,2-diyl) tetraoctanoate;
(R)-4-(3((S)-3,4-bis(octanoyloxy)butoxy)-5-((dimethylamino)methyl)phenoxy)butane-1,2-diyl dioctanoate;
(5)-4-(3-((S)-3,4-bis(octanoyloxy)butoxy)-5-((dimethylamino)methyl)phenoxy)butane-1,2-diyl dioctanoate;
(R)-4-(3-(R)-3,4-bis(octanoyloxy)butoxy)-5-((dimethylamino)methyl)phenoxy)butane-1,2-diyl dioctanoate;
2-(3-(4-(5-((dimethylamino)methyl)-2-methyl-3((9Z,12Z)-octadeca-9,12-dien-1-yloxy)phenoxy)butoxy)-3-oxopropyl)propane-1,3-diyl dihexanoate;
(((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl))bis(propane-3,2,1-triyl) tetraoctanoate;
(((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(methylene))bis(propane-3,2,1-triyl) tetraoctanoate; and
((((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl))bis(oxy))bis(propane-3,2,1-triyl) tetraoctanoate; or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,793,641

FULLY HUMAN ANTI-MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN

CARSGEN THERAPEUTICS CO.,...

1. An antibody that specifically binds to mesothelin, wherein the antibody is at least one selected from the group consisting of:(a) an antibody comprising:
a heavy chain variable region having VH CDR1 comprising the amino acid sequence of SEQ ID NO: 54, VH CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and VH CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and
a light chain variable region having VL CDR1 comprising the amino acid sequence of SEQ ID NO: 51, VL CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and VL CDR3 comprising the amino acid sequence of SEQ ID NO: 53,
(b) an antibody comprising:
a heavy chain variable region having VH CDR1 comprising the amino acid sequence of SEQ ID NO: 60, VH CDR2 comprising the amino acid sequence of SEQ ID NO: 61, and VH CDR3 of the amino acid sequence of SEQ ID NO: 62; and
a light chain variable region having VL CDR1 comprising the amino acid sequence of SEQ ID NO: 57, VL CDR2 comprising the amino acid sequence of SEQ ID NO: 58 and VL CDR3 of the amino acid of ID NO: 59,
(c) an antibody comprising:
a heavy chain variable region comprising the amino acid sequence shown in positions 1 to 123 of SEQ ID NO: 6; and
a light chain variable region comprising the amino acid sequence shown in positions 139-254 of SEQ ID NO: 6, and
(d) an antibody comprising:
a heavy chain variable region comprising the amino acid sequence shown in positions 1 to 124 of SEQ ID NO: 8; and
a light chain variable region comprising the amino acid sequence shown in positions 140-247 of SEQ ID NO: 8.
US Pat. No. 10,793,898

NANO-SENSORS FOR NUCLEIC ACID DETECTION AND DISCRIMINATION

THE REGENTS OF THE UNIVER...

1. A nucleic acid detection device, comprising:a graphene chip that comprises a substrate, a graphene surface on the substrate, a conducting substance at two ends of the graphene surface to form a first electrode and a second electrode, and an insulating substance to insulate the first electrode and the second electrode, wherein the insulating substance further forms a solution reservoir on the graphene surface to receive a nucleic acid probe and a sample nucleic acid;
a double-stranded nucleic acid probe attached to the graphene surface of the reservoir, wherein the nucleic acid probe comprises a normal strand having a toehold at one end and a weak strand comprising one or more inosines substituting guanines; and
a microcontroller board that comprises a digital meter to measure electric current that passes through the graphene chip when an input voltage is applied to the graphene chip, and a communication module to send values of the measured electric current and the input voltage, wherein the microcontroller board further comprises a low-pass filter to filter input voltage.
US Pat. No. 10,795,180

OPHTHALMIC LENS AND METHOD FOR MANUFACTURING THE SAME

BenQ Materials Corporatio...

1. A contact lens, comprising:a lens body; and
an antimicrobial hydrophilic layer formed on a surface of the lens body, wherein the antimicrobial hydrophilic layer comprising:
a polydopamine layer formed on the surface of the lens body by immersing the lens body in a polydopamine solution prepared from dopamine in alkaline environments and heating at the temperature in the range of 35° C. to 100° C. for a period of time in the range of 5 minutes to 60 minutes; and
a zwitterionic polymer non-covalently bonded on the polydopamine layer, wherein the zwitterionic polymer is selected from one of the group consisting of phosphorylcholine polymer, sulfobetaine polymer, carboxybetaine polymer, mixed-charge polymer and a combination thereof;
wherein the polydopamine layer is substantially colorless on the contact lens; and
wherein the visible light transmittance of the contact lens is not less than 90%.
US Pat. No. 10,792,874

METHOD OF MAKING SILICONE CONTAINING CONTACT LENS WITH REDUCED AMOUNT OF DILUENTS

1. A contact lens that is a reaction product of a reactive mixture comprising (a) at least one hydroxy-containing silicone component having a weight average molecular weight from about 200 to about 15,000 g/mole and (b) at least one monofunctional polyethylene glycol having a weight average molecular weight from about 200 to about 10,000 g/mole; and less than about 15 wt % diluents, wherein the contact lens comprises a polymer having a Tg (heating) of less than 125° C.
US Pat. No. 10,793,642

BINDING MEMBERS FOR HUMAN C-MAF

INBIOMOTION S.L., Barcel...

1. A binding member that specifically binds to human c-MAF, wherein the binding member comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 38, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 40, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 30.
US Pat. No. 10,793,899

METHODS FOR IDENTIFYING HYDROXYLATED BASES

THE UNITED STATES OF AMER...

1. A method comprising: performing an imaging method to detect a moiety associated with a glucosylated 5-hydroxymethylated cytosine in a nucleic acid that is from an extracellular fluid sample.
US Pat. No. 10,792,363

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

FENNEC PHARMACEUTICALS, I...

1. Anhydrous sodium thiosulfate characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks selected from 10.52, 15.13, 17.71, 19.70, 21.09, 21.49, 21.84, 27.40, 28.96, 30.46, 31.81, 32.52, 33.15, 37.40, or 38.16 degrees 2 theta (2 ?)±0.2, when the XRPD is collected from about 2 to about 40 degrees 2 ? using copper K? radiation.
US Pat. No. 10,793,643

PCSK9 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF

Jiangsu Hengrui Medicine ...

1. A PCSK9 antibody or the antigen-binding fragment thereof, wherein the antibody comprises a HCDR1, a HCDR2, and a HCDR3 as shown in SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, respectively; anda LCDR1, a LCDR2, and a LCDR3 as shown in SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, respectively.
US Pat. No. 10,793,900

POLYPEPTIDE SPECIFICALLY BINDING TO TAQ DNA POLYMERASE AND USE THEREOF

ENZYNOMICS CO. LTD., Dae...

1. A repebody polypeptide which binds specifically to Taq DNA polymerase, the polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 3 to 13.
US Pat. No. 10,792,364

TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS

PURDUE PHARMA L.P., Stam...

1. A method of treating pain comprising administering to a patient in need thereof, a solid oral dosage form comprising:a heat-labile gelling agent;
a thermal stabilizer comprising an anionic polymer in a neutral pH aqueous solution; and
an analgesic drug susceptible to abuse,
wherein the solid oral dosage form releases at least about 85% of the drug susceptible to abuse within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C.
US Pat. No. 10,793,647

METHOD FOR PRODUCTION OF CELLULOSE NANOCRYSTALS FROM MISCANTHUS GIGANTEUS AND COMPOSITES THEREFROM

CASE WESTERN RESERVE UNIV...

1. A composite composition, comprising:a matrix material; and cellulose nanocrystals from Miscanthus Giganteus having carboxyl functionality,wherein the matrix material comprises one or more polymers or copolymers,
wherein the polymers or copolymers comprise an alkylene oxide (co)polymer, a vinyl aromatic (co)polymer, a polyolefin (co)polymer, a diene (co)polymer, a polyacrylate (co)polymer, poly(vinyl acetate), poly(vinyl alcohol), a polyimide, a polyurethane, a polyester, or a combination thereof,
wherein the nanocrystals are derived from a process comprising the steps of:
performing a base hydrolysis step on a quantity of the Miscanthus Giganteus;
performing a bleaching step on a solid material recovered from the base hydrolysis step;
performing an acid hydrolysis step on a solid material recovered from the bleaching step; and
recovering cellulose nanocrystals from the Miscanthus Giganteus after performing the acid hydrolysis step.
US Pat. No. 10,793,648

FUCOSE-CONTAINING BACTERIAL BIOPOLYMER

1. A process for synthesizing a polymer comprising a fucose-containing polysaccharide, the process comprising:a) a batch phase comprising cultivating a microbial culture in a culture medium in a stirred and aerated bioreactor, wherein the culture medium comprises a carbon source, a nitrogen source and inorganic salts; and
b) a fed-batch phase comprising cultivating the microbial culture under conditions of carbon availability and nitrogen limitation that results in the synthesis of the fucose-containing polysaccharide, wherein the fucose-containing polysaccharide comprises:
(i) an amount of fucose which is at least 10% of the total carbohydrate content of the fucose-containing polysaccharide;
(ii) acyl groups in an amount up to 25% of the dry weight of the polysaccharide, wherein the acyl groups comprise succinate, pyruvate, and acetate, and wherein the amount of pyruvate is up to 5% of the dry weight of the fucose-containing polysaccharide; and
(iii) an amount of glucose which is between 20-70% of the total carbohydrate content of the fucose-containing polysaccharide,wherein the microbial culture comprises microorganisms of the genera Pseudomonas, Klebsiella, Methylobacterium, Erwinia, Alcaligenes or Enterobacter.
US Pat. No. 10,793,649

METHOD OF FORMING A MICROPHASE SEPARATED BLOCK COPOLYMER AND MICROPHASE SEPARATED BLOCK COPOLYMER

THE UNIVERSITY OF MASSACH...

1. A method of forming a gradient microphase separated block copolymer film, the method comprising:exposing a block copolymer film comprising
a first hydrophobic block; and
a second hydrophobic block, wherein the second hydrophobic block is acid-sensitive;
to acid vapor under conditions effective to provide the gradient microphase separated block copolymer comprising
a first portion adjacent to a first edge of the film, wherein the first portion is microphase separated and comprises domains comprising the first hydrophobic block and domains comprising a hydrophilic block derived from the second hydrophobic block;
a gradient portion exhibiting a microphase separation gradient extending from the first portion to a second, opposite edge of the film; and
optionally, a second portion, wherein the second portion is phase-mixed and comprises the block copolymer comprising the first hydrophobic block and the second hydrophobic block, provided that when the second portion is present, the second portion is adjacent to the second, opposite edge of the film and the gradient portion extends from the first portion to the second portion; and
thermally annealing the gradient microphase separated block copolymer film;
wherein the exposing is conducted in the solid state.
US Pat. No. 10,793,905

METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES

10X GENOMICS, INC., Plea...

1. A method of cellular analysis, comprising:(a) contacting a cell with an antibody to provide said cell bound to said antibody, wherein said antibody comprises a reporter oligonucleotide comprising a reporter barcode sequence that is an identifier of said antibody, and wherein said cell comprises a genomic deoxyribonucleic acid (DNA) molecule;
(b) providing a partition comprising said reporter oligonucleotide, said genomic DNA molecule of said cell, and a bead comprising, attached thereto: (i) a first nucleic acid barcode molecule comprising a cell barcode sequence, and (ii) a second nucleic acid barcode molecule comprising said cell barcode sequence;
(c) using said first nucleic acid barcode molecule and said reporter oligonucleotide to generate a first barcoded product comprising (i) said reporter barcode sequence or reverse complement thereof and (ii) said cell barcode sequence or reverse complement thereof; and
(d) using said second nucleic acid barcode molecule and said genomic DNA molecule to generate a second barcoded product comprising (i) a sequence of said genomic DNA molecule or reverse complement thereof and (ii) said cell barcode sequence or a reverse complement thereof.
US Pat. No. 10,793,650

METHOD FOR PRODUCING LOW MOLECULAR WEIGHT POLYTETRAFLUOROETHYLENE, LOW MOLECULAR WEIGHT POLYTETRAFLUOROETHYLENE, AND POWDER

DAIKIN INDUSTRIES, LTD., ...

1. Powder comprising low molecular weight polytetrafluoroethylene,the low molecular weight polytetrafluoroethylene having a complex viscosity of 1×102 to 7×105 Pa·s at 380° C. and containing 5 or less carboxyl groups at ends of the molecule chain per 106 carbon atoms in the main chain,
the powder being substantially free from C8-C14 perfluorocarboxylic acids and salts thereof,
wherein the low molecular weight polytetrafluoroethylene (i) consists of a tetrafluoroethylene (TFE) unit or (ii) comprises a TFE unit and of all the monomer units, 0.001 to 1 mass % of a modifying monomer unit based on a modifying monomer copolymerizable with TFE.
US Pat. No. 10,793,906

METHODS FOR TREATING AND DETECTING SEPSIS IN HUMANS

CNA DIAGNOSTICS INC., Ca...

1. A method for treating sepsis comprising administering to a human identified as having sepsis a therapeutically effective amount of at least one agent used to treat sepsis, wherein the human is identified as having sepsis by analyzing a serum sample comprising analyzing the level of circulating nucleic acid from the human serum sample for circulating nucleic acids of SEQ ID NO 10-30 and SEQ ID NOs: 59, 61 and 68 to detect under-representation of at least one nucleic acid sequence having at least 95% identity to SEQ ID NOs: 10-30 relative to a nucleic acid sequence having at least 95% identity to SEQ ID NOs: 59, 61 and 68 to identify the human as having sepsis.
US Pat. No. 10,792,370

ANTIBODY-DRUG CONJUGATE

SHANGHAI MIRACOGEN INC, ...

1. An antibody-drug conjugate or a pharmaceutically acceptable salt thereof, comprising an anti-epidermal growth factor receptor antibody covalently linked to a cytotoxic agent via a cleavable linker, wherein the anti-epidermal growth factor receptor antibody comprises a heavy chain and a light chain, wherein the heavy chain has a variable region comprising CDR1, CDR2 and CDR3 having sequences as shown in SEQ ID NOs: 5 to 7, and the light chain has a variable region comprising CDR1, CDR2 and CDR3 having sequences as shown in SEQ ID NOs: 12 to 14.
US Pat. No. 10,793,907

METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR ENDOCRINE SYSTEM CONDITIONS

PSOMAGEN, INC., Rockvill...

1. A method for diagnosing and treating Graves' disease, the method comprising:at a sample handling network, processing content of a sample from a subject, thereby generating a microbiome composition dataset and a microbiome functional diversity dataset associated with the sample;
at a computing system in communication with the sample handling network, identifying an association between the sample and at least one of a taxonomic feature from the microbiome composition dataset and a functional feature from the microbiome functional diversity dataset;
based upon the association, diagnosing the subject with Graves' disease; and
providing a therapy to the subject, wherein providing the therapy comprises promoting a microbiome modifying therapy to the subject in order to improve a health state of the subject with Graves' disease.
US Pat. No. 10,792,371

C-MET TARGETING COMPOUND-BIOACTIVE MATERIAL CONJUGATE AND USE THEREOF

SAMSUNG ELECTRONICS CO., ...

1. A antibody-drug conjugate comprising an anti-c-Met antibody and a cytotoxic agent, in which the anti-c-Met antibody and the cytotoxic agent are conjugated with each other,wherein the anti-c-Met antibody binds to an epitope comprising a sequence of 5 to 19 consecutive amino acids of SEQ ID NO: 71 including the amino acid sequence EEPSQ (SEQID NO: 73) and comprises:
a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, 22, 23, or 24;
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 25, or 26;
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, 27, 28, or 85;
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10, 29, 30, 31, 32, 33, or 106;
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11, 34, 35, or 36; and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13, 14, 15, 16, or 37.
US Pat. No. 10,792,883

COATED CONDUITS AND METHODS OF REPAIRING OR REINFORCING CONDUITS

PPG Coatings Europe B.V.,...

1. A coated conduit, comprising:a) a conduit having an interior and exterior surface; and
b) a cured coating formed from a reaction mixture that is applied to at least one surface of the conduit, wherein the reaction mixture comprises:i) a filler material comprising fibers ranging in length from 0.1 to 15.54 cm and having an aspect ratio of at least 5; andii) a reactive component that demonstrates a tack-free time of less than five minutes at a temperature of 20 to 25° C.
US Pat. No. 10,793,908

METHOD FOR THE DIAGNOSIS OF DISORDERS CAUSED BY FETAL ALCOHOL SYNDROME

Centre Hospitalier Univer...

1. A method of treatment of foetal alcohol spectrum disorders (FASDs) in a subject believed to be suffering from an FASD comprising the following steps:a) measuring the amount of placental growth factor (PIGF) in a biological sample from said subject by measuring the amount of the polypeptide;
b) comparing the amount of PIGF from step a) with a reference;
c) verifying an FASD in said subject, and
d) treating a subject verified to have an FASD.
US Pat. No. 10,793,909

METHODS FOR PREDICTING THE SURVIVAL TIME OF PATIENTS WITH DECOMPENSATED ALCOHOLIC CIRRHOSIS

INSERM (INSTITUT NATIONAL...

1. A method of treating a patient with decompensated alcoholic cirrhosis having a decreased survival time comprisingi) determining the mRNA expression level of OAS2 or MX2 in a sample of peripheral blood mononuclear cells obtained from the patient,
ii) comparing the level determined at step i) with the mRNA expression level of OAS2 or MX2 in healthy subjects,
iii) determining that the patient will have a decreased survival time when the level determined at step i) is higher than the mRNA expression level of OAS2 or MX2 in healthy subjects, and
iv) performing liver transplantation on the patient determined to have a decreased survival time.
US Pat. No. 10,793,910

CYSTIC FIBROSIS GENE MUTATIONS

Quest Diagnostics Investm...

1. A method of detecting a mutant cystic fibrosis transmembrane (CFTR) nucleic acid in an individual, comprising: (a) contacting a biological sample comprising a CFTR nucleic acid from an individual with a detectably labeled nucleic acid probe that specifically hybridizes to a mutant CFTR nucleic acid comprising the mutation but not to a wild-type CFTR nucleic acid; wherein the mutation is c.2846A>T, and the probe comprises the mutation and (b) detecting thymidine at c.2846A>T in the individual, wherein the individual is suspected of having a CFTR gene mutation associated with cystic fibrosis.
US Pat. No. 10,793,911

HOST DNA AS A BIOMARKER OF CROHN'S DISEASE

ENTEROME, Paris (FR)

1. A method for treating a subject suffering from Crohn's disease (CD), comprising:providing a stool sample from a subject suffering from Crohn's disease, wherein the stool sample comprises subject DNA;
performing an assay to quantify the relative abundance of subject DNA in the sample; and
administering a CD treatment to the subject when the relative abundance of the subject DNA is above 1%.
US Pat. No. 10,792,375

METHOD FOR THE TREATMENT OF MALIGNANCIES

University of South Flori...

21. A method of reducing angiogenesis in at least one tumor comprising: injecting the at least one tumor with an effective dose of at least one plasmid coding for IL-12; and administering electroporation therapy to the tumor, the electroporation therapy comprising the administration of at least one pulse having a field strength of at least 400V/cm and a duration of less than 1 millisecond resulting in reduction of angiogenesis in the at least one tumor, wherein the electroporation therapy comprises no more than six pulses.
US Pat. No. 10,793,912

METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI

Natera, Inc., San Carlos...

1. A method for determining genetic mutations from an individual, comprising:determining whether a genetic mutation is present by analyzing a biological sample from the individual to determine a level of allelic imbalance for each of a plurality of chromosomes or chromosome segments known to exhibit cancer-associated mutations by:
amplifying at least 10 polymorphic loci relating to the cancer-associated mutations from each of the plurality of chromosomes or chromosome segments of circulating tumor DNA in the biological sample from the individual to obtain amplicons, wherein the amplifying comprises a first PCR to simultaneously amplify the at least 10 polymorphic loci by contacting the biological sample with at least 10 non-identical primers that simultaneously hybridize to the at least 10 polymorphic loci, followed by a second, nested PCR to simultaneously amplify the at least 10 polymorphic loci with at least 10-non-identical inner primers, wherein the polymorphic loci are single nucleotide variance loci,
generating nucleic acid sequence data for a set of polymorphic loci on each of the plurality of chromosomes or chromosome segments by performing high throughput sequencing of the amplicons, wherein more than 80% of the amplicons map to the targeted polymorphic loci,
using the nucleic acid sequence data to generate allelic data for the set of polymorphic loci on each of the plurality of chromosomes or chromosome segments, and
determining the level of allelic imbalance for each of the plurality of chromosomes or chromosome segments using the allelic data, wherein a detectable allelic imbalance is indicative of a genetic mutation.
US Pat. No. 10,792,376

AFFENADENOVIRUS (GORILLA) OR ADENOVIRAL VECTORS AND METHODS OF USE

GenVec, Inc., Gaithersbu...

1. A method of delivering a non-native nucleic acid sequence to mammalian cells in vivo, wherein the method comprises in vivo administration of an adenovirus or adenoviral vector comprising the non-native nucleic acid sequence and one or more of the nucleic acid sequences selected from the group consisting of: (a) a nucleic acid sequence that is at least 96% identical to SEQ ID NO: 1, (b) a nucleic acid sequence that is at least 99% identical to SEQ ID NO: 2, (c) a nucleic acid sequence that is at least 80% identical to SEQ ID NO: 3, (d) a nucleic acid sequence that is at least 80% identical to SEQ ID NO: 4; and (e) a nucleic acid sequence that is at least 85.4% identical to SEQ ID NO: 5.
US Pat. No. 10,793,913

METHODS AND COMPOSITIONS FOR TREATMENT OF BREAST CANCER

City of Hope, Duarte, CA...

1. A method of measuring a level of miR-105 in a subject that has a breast cancer, the method comprising the steps of:(a) obtaining a serum-derived biological sample from the subject that has the breast cancer;
(b) measuring a level of miR-105 in the serum-derived biological sample, wherein the measuring comprises performing a nucleic acid hybridization;
(c) detecting an increased level of miR-105 in said serum-derived biological sample compared to a control; and
(d) administering to said subject an antisense oligonucleotide inhibitor of miR-105.
US Pat. No. 10,793,914

CANCER-RELATED BIOLOGICAL MATERIALS IN MICROVESICLES

THE GENERAL HOSPITAL CORP...

4. A method for determining the expression level of a retrotransposon element in a microvesicle from a subject comprising the steps of:a. isolating microvesicles derived from a tumor cell from the subject;
b. treating the isolated microvesicles with a combination of DNAse and Exonuclease III;
c. extracting at least one nucleic acid from the treated microvesicles; and
d. determining the expression level of the retrotransposon element biomarker in the extracted nucleic acid.
US Pat. No. 10,792,378

USING A BLUE-SHIFTED REFERENCE DYE IN AN OPTICAL GLUCOSE ASSAY

Medtronics MiniMed, Inc.,...

1. A glucose sensing complex comprising:a glucose binding agent coupled to an assay fluorophore; and
a glucose analog coupled to a reference fluorophore;
wherein:
the reference fluorophore is blue shifted relative to the assay fluorophore;
the assay fluorophore exhibits a wavelength that is at least 50 nanometers greater than the wavelength of the reference fluorophore; and
the assay fluorophore and reference fluorophore are individually selected from the group consisting of Alexa Fluor 594 (AF594), Alexa Fluor 647 (AF647), and Alexa Fluor 700 (AF700), and wherein the reference fluorophore has a lower wavelength than the assay fluorophore.
US Pat. No. 10,793,916

SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION

GUARDANT HEALTH, INC., R...

1. A method for inferring a quantitative measure of microsatellite changes in a sample of cell-free nucleic acid molecules from a subject having a cancer, the method comprising:(a) tagging a plurality of the cell-free nucleic acid molecules from the sample with molecular barcodes from a set of molecular barcodes to produce tagged parent polynucleotides;
(b) amplifying a plurality of the tagged parent polynucleotides to produce amplified tagged progeny polynucleotides;
(c) sequencing a plurality of the amplified tagged progeny polynucleotides to produce a set of sequencing reads;
(d) grouping a plurality of sequencing reads from the set of sequencing reads into families based at least on sequence information of the molecular barcodes, each family having sequencing reads amplified from a same tagged parent polynucleotide from among the tagged parent polynucleotides;
(e) determining a quantitative measure of sequencing reads in a plurality of the families and a quantitative measure of unique families from among a plurality of the families;
(f) inferring a number of the tagged parent polynucleotides based on the quantitative measure of the sequencing reads in the plurality of the families and the quantitative measure of unique families from among the plurality of the families;
(g) determining a quantitative measure of microsatellite changes from among a plurality of the families; and
(h) based on the determined quantitative measure of microsatellite changes from among the plurality of the families, inferring a quantitative measure of microsatellite changes in the inferred number of the tagged parent polynucleotides.
US Pat. No. 10,793,661

SYNTHESIS OF STAR ISOBUTYLENE-BASED THERMOPLASTIC ELASTOMERS

THE UNIVERSITY OF AKRON, ...

1. A method of producing a star block copolymer comprising (a) a core component having a styrene oligomer or ?-methyl styrene oligomer; and (b) arms emanating from the core component wherein the arms are poly(isobutylene-block-styrene) diblock copolymers, the method including the steps of:a. cationically synthesizing the styrene oligomer or ?-methyl styrene oligomer;
b. acetylating the styrene oligomer or ?-methyl styrene oligomer to form a styrene oligomer or ?-methyl styrene oligomer with acetyl groups;
c. converting the acetyl groups to cumyl hydroxide groups;
d. undertaking living carbocationic polymerization of isobutylene to form polyisobutylene blocks; and
e. undertaking living carbocationic polymerization of styrene to form polystyrene blocks at an end of each polyisobutylene block to provide the poly(isobutylene-block-styrene) diblock copolymer arms.
US Pat. No. 10,793,917

METHOD AND KIT OF DETECTING THE ABSENCE OF MICRO-ORGANISMS

MOMENTUM BIOSCIENCE LIMIT...

1. A method of detecting the presence of a micro-organism in a sample, the method comprising:(a) contacting the sample with a nuclease resistant nucleic acid molecule comprising a plurality of nuclease resistant nucleotides which is either extended by polymerase activity or is ligated by ligase activity of the micro-organism in the sample, wherein the nuclease resistant nucleotides comprise phosphorothioate nucleotides,
(b) incubating the thus contacted sample under conditions suitable for polymerase activity or ligase activity; and
(c) detecting in the sample a nucleic acid molecule that has been extended by the polymerase activity or ligated by the ligase activity of the micro-organism as compared to a negative control, thereby indicating the presence of the micro-organism in the sample.
US Pat. No. 10,792,637

METHOD FOR FEEDING A FLUID TO A GAS PHASE POLYMERIZATION REACTOR

Basell Poliolefine Italia...

1. A method for feeding a fluid into a polymer bed of a fluidized bed gas phase polymerization reactor comprising the step of:introducing a controlled and continuous flow rate of the fluid into the polymer bed through a distributor protruding into the fluidized bed zone of the reactor and terminating with a discharge end positioned so that the following equation is fulfilled:
d/D>0.002
wherein d is the distance of the distributor's discharge end from the wall of the reactor, and D is the diameter of the reactor in the fluidized bed zone
wherein a head loss is generated through orifices in the distributor such that a Reynolds number (Re) of from 10000 to 700000 is achieved.
US Pat. No. 10,793,918

MOLECULAR MARKERS FOR BLACKLEG RESISTANCE IN CANOLA AND METHODS OF USING THE SAME

Dow AgroSciences LLC, In...

1. A method for identifying a first parent canola plant or germplasm that comprises a marker allele for blackleg resistance in a breeding program, the method comprising:obtaining a nucleic acid sample from a first parent canola plant or germplasm;
detecting in the nucleic acid sample at least one single nucleotide polymorphism (SNP) marker allele for blackleg resistance selected from the group consisting of DBSNP10503 (SEQ ID NO:24), DBSNP10504 (SEQ ID NO:25), DBSNP31606 (SEQ ID NO:23), DBSNP30220 (SEQ ID NO:22), DBSNP01654 (SEQ ID NO:26), DBSNP01910 (SEQ ID NO:27), DBSNP05704 (SEQ ID NO:28), DBSNP05705 (SEQ ID NO:29), DBSNP28066 (SEQ ID NO:17), DBSNP27644 (SEQ ID NO:18), DBSNP28099 (SEQ ID NO:19), DBSNP33158 (SEQ ID NO:20), BSNP14607 (SEQ ID NO:21), DBSNP04906 (SEQ ID NO:31), DBSNP07219 (SEQ ID NO:30), DBSNP08872 (SEQ ID NO:32), DBSNP08485 (SEQ ID NO:34), DBSNP00547 (SEQ ID NO:33), DBSNP08169 (SEQ ID NO:35), DBSNP00787 (SEQ ID NO:36), and DBSNP01590 (SEQ ID NO:37);
selecting the first parent canola plant or germplasm thereof based on the presence of the SNP marker allele for blackleg resistance in the sample; and
crossing the first parent canola plant with a second parent canola plant to produce a population comprising progeny canola plants or germplasm having the SNP marker allele.
US Pat. No. 10,793,663

POLYURETHANE FOAM AND A POLYURETHANE COMPOSITE COMPRISING THE SAME

COVESTRO DEUTSCHLAND AG, ...

1. An isocyanate reactive component B) comprising a polyether polyol composition, the polyether polyol composition comprising:b1) 30-40 mol-%, based on the theoretically calculated total mole number of the polyether polyol composition, of a first polyether polyol, having a functionality of 1.6-2.4, a hydroxyl value of 60-140 mg KOH/g,
b2) 35-55 mol-%, based on the theoretically calculated total mole number of the polyether polyol composition, of a second polyether polyol, having a functionality of 7.6-8.4, a hydroxyl value of 480-560 mg KOH/g, and
b3) 13-27 mol-%, based on the theoretically calculated total mole number of the polyether polyol composition a third polyether polyol, selected from polyether polyols derived from diphenylmethane diamine and/or toluenediamine, having a functionality of 3.6-4.4, and a hydroxyl value of 290-370 mg KOH/g.
US Pat. No. 10,793,919

METHODS FOR DETERMINING FITNESS IN PLANTS

BASF SE, Ludwigshafen am...

1. A method for preparing a Brassica plant with a high energy use efficiency from a collection of plants from the same species or variety which are genetically uniform plants comprising the steps of:a) providing a population consisting of a plurality of individual Brassica plants which are genetically uniform;
b) obtaining a genomic DNA sample from individual plants of said population at least at a first and a second developmental stage in a manner which allows further cultivation of said sampled individual plants, wherein said first developmental stage is the cotyledon stage and said second developmental stage is the third leaf stage of said plant;
c) determining of each of said individual plants a methylation profile of said genomic DNA obtained at said at least two stages;
d) determining the epigenetic features of each of said individual plants by evaluating the changes in DNA methylation profile between said first and said second stage; and
e) identifying and selecting at least one plant which has a high relative occurrence of at least five epigenetic features characteristic for high energy use efficiency when compared to the average occurrence of said epigenetic features in other plants of said population, wherein said epigenetic features are selected from: mCTC-gain, mCG-gain, mCTG-loss, mCTT-loss, and mCCG-loss.
US Pat. No. 10,792,895

COLORED LIGHT EMITTING SHEET AND COLORED LIGHT EMITTING GLASS

SEKISUI CHEMICAL CO., LTD...

1. A colored luminescent sheet comprising:a thermoplastic resin;
calcium carbonate as a white pigment; and
a luminescent material that emits visible light having a wavelength of 380 to 750 nm under excitation light.
US Pat. No. 10,793,664

PROCESS FOR PREPARING TRIMERS AND/OR OLIGOMERS OF DIISOCYANATES

Evonik Operations GmbH, ...

1. A composition of trimers and/or oligomers formed from diisocyanates and monomeric diisocyanates, the composition comprising the reaction product ofI. from 5 to 94.999% by weight of
A) an aliphatic and/or cycloaliphatic diisocyanate having a boiling point of less than 250° C. (at standard pressure)
and/or
B) an aliphatic and/or cycloaliphatic diisocyanate having a boiling point of from 250 to 350° C. (at standard pressure),
in the presence of
II. from 94.999 to ?5% by weight of
C) a diisocyanate having a boiling point above 350° C. (at standard pressure) wherein the diisocyanate is selected from the group consisting of dicyclohexylmethylene diisocyanate (H12MDI) and octadecane diisocyanate,
III. in the presence of at least one trimerization catalyst in amounts of from 0.001% to 5% by weight,
and the amounts of add up to 100% by weight,
where the proportion of monomeric A) and/or monomeric B) after the reaction in the mixture, based on the overall mixture of A)+B)+C), in absolute terms is not greater than 10% by weight, and based on the diisocyanate A) and/or B) used is not greater than 20% by weight in relative terms.
US Pat. No. 10,793,920

METHODS AND COMPOSITIONS FOR IDENTIFYING YEAST

MYCODART, INC., Carrollt...

1. A method of identifying a specific yeast species in patient tissue or body fluid, the method comprising the steps of:extracting and recovering DNA of the yeast species from the patient tissue or body fluid;
amplifying the DNA;
hybridizing a probe to the DNA to specifically identify the yeast species, wherein the probe sequence is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 10, a full complement of the sequence of SEQ ID NO: 4, and a full complement of the sequence of SEQ ID NO: 10; and
specifically identifying the yeast species, wherein the yeast species is Candida glabrata or Candida tropicalis.
US Pat. No. 10,795,970

METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR LOCOMOTOR SYSTEM CONDITIONS

PSOMAGEN, INC., Rockvill...

1. A method for at least one of characterizing, diagnosing, and treating a locomotor condition in a subject, the method comprising:receiving an aggregate set of samples from a population of subjects comprising at least one sample associated with the locomotor condition;
for each sample of the aggregate set of samples:
determining a microorganism sequence, comprising: selecting a primer for a nucleic acid sequence and amplifying nucleic acid material from the sample using the selected primer; and
determining an alignment of the microorganism sequence to a reference sequence;
generating a microbiome feature dataset, including diversity features, for the population of subjects based upon the alignments;
generating a characterization of the locomotor condition from features extracted from the microbiome feature dataset and a supplementary dataset informative of characteristics associated with the locomotor condition;
based upon the characterization, generating a therapy model that determines a therapy for correcting the locomotor condition; and
providing the therapy to the subject with the locomotor condition based upon the characterization and the therapy model.
US Pat. No. 10,792,384

ROLLED FIBROUS STRUCTURES COMPRISING ENCAPSULATED MALODOR REDUCTION COMPOSITIONS

1. A roll of fibrous structure comprising:a core upon which the fibrous structure is convolutely wound;
wherein the core comprises one or more malodor reduction compositions encapsulated by a polymer shell and capable of being released upon rupture of the polymer shell;
wherein the polymer shell comprises polyacrylate;
wherein at least one of the malodor reduction compositions comprises one or more carrier materials.
US Pat. No. 10,793,665

POLYURETHANE FOAM FROM HIGH FUNCTIONALITY POLYISOCYANATE

DDP SPECIALTY ELECTRONIC ...

1. A polyisocyanurate foam comprising the reaction product of a formulation system comprising:(a) a pre-polymer that is a reaction product of a polymeric isocyanate and a polyether polyol, where:
(i) the polymeric isocyanate contains five weight-percent or more methylene diphenyl diisocyanate based on total polymeric isocyanate weight;
(ii) the polymeric isocyanate has a functionality of 3.0 or less;
(iii) the polyether polyol is present in the pre-polymer at a concentration of one weight-percent or more and 25 weight-percent or less based on total pre-polymer weight;
(iv) the polyether polyol has an equivalent weight of 50 or more and 500 or less grams per equivalent;
(v) the NCO concentration of the pre-polymer is 15 weight-percent or more and 31 weight-percent or less based on total pre-polymer weight as determined according to ASTM D2572;
(vi) The pre-polymer is free of isocyanate trimers as determined by nuclear magnetic resonance spectroscopy; and
(b) a polyester polyol component comprising 10 weight-percent or more and 25 weight-percent or less of free glycol based on total polyester polyol component weight and the balance being polyester polyol; and
(c) a blowing agent that contains less than five weight-percent water based on total blowing agent weight;where the ratio of pre-polymer and polyester polyol are such that, when mixed together they result in foam having a trimer content of 12 weight-percent or more and 22 weight-percent or less based on total polymer weight in the foam, and an NCO index of more than 300 and less than 700; and wherein the polyisocyanurate foam has a density of 24 kilograms per cubic meter or more and 48 kilograms per cubic meter or less as determined by ASTM 1622.
US Pat. No. 10,793,921

LOW-LEAKAGE CELLULAR BIOSENSOR SYSTEM

ETH ZURICH, Zurich (CH)

1. A cellular biosensor system comprising:at least one first gene comprising:
1.1 a first gene promoter sequence,
1.2 a sequence encoding a transcriptional activator protein that is operably linked to the first gene promoter sequence,
1.3 at least one target site-1 for one or more chemical inputs,
wherein upon chemical input binding, the target site-1 is capable of inhibiting or repressing the expression of the transcriptional activator that is operably linked to the first gene promoter sequence;
at least one second gene comprising:
2.1 a second gene promoter inducible by the transcriptional activator protein, and that is operably linked to either,
(i) a sequence encoding a transcriptional repressor and at least one target site-2 for one or more chemical inputs, and/or
(ii) one or more repressor sequences encoding at least one repressor microRNA,
wherein:
upon chemical input binding, the target site-2 is capable of inhibiting or repressing the expression of the transcriptional repressor, and
the transcriptional repressor and/or the at least one repressor microRNA inhibits or represses the expression of at least one output sequence by repressing transcription from a third gene promoter sequence;
at least one third gene comprising:
3.1 the third gene promoter sequence that is repressible by the transcriptional repressor of the second gene when the second gene comprises the transcriptional repressor,
3.2 at least one output sequence,
3.3 at least one sequence(s) enabling gene rearrangement in the presence of at least one site-specific recombinase,
3.4 at least one micro RNA microRNA target site for the at least one repressor microRNA, if when the second gene comprises one or more repressor sequences encoding at least one repressor microRNA,
wherein upon gene rearrangement in the presence of at least one site-specific recombinase, the third gene promoter is operably linked to the output sequence such that the output sequence is expressed; and
at least one fourth gene comprising:
4.1 at least one fourth gene promoter, and
4.2 a sequence encoding the site-specific recombinase that enables gene rearrangement in the third gene that is operably linked to the fourth gene promoter.
US Pat. No. 10,795,971

METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR LOCOMOTOR SYSTEM CONDITIONS

PSOMAGEN, INC., Rockvill...

1. A method for characterizing a gout condition for a subject, the method comprising:for each sample of an aggregate set of samples comprising at least one sample comprising microorganisms associated with the gout condition:
determining a microorganism nucleic acid sequence upon amplifying nucleic acid material of the sample using a set of primers; and
determining an alignment of the microorganism nucleic acid sequence to a reference nucleic acid sequence;
generating a microbiome feature dataset, comprising diversity features, based on the alignments;
generating a characterization of the gout condition based on the microbiome feature dataset;
determining a therapy for the subject based on the characterization and a subject sample from the subject; and
providing the therapy to the subject, wherein the therapy is operable to modulate microbiome composition to improve a state of the gout condition.
US Pat. No. 10,792,641

STRUCTURE

FUJI XEROX CO., LTD., To...

1. A structure comprising:a base material; and
a surface layer that contains a binder resin and a titanium compound particle having absorption at 450 nm and 750 nm in a visible absorption spectrum and a BET specific surface area within a range of 100 m2/g to 1200 m2/g,
wherein the titanium compound particle is a metatitanic acid particle.
US Pat. No. 10,793,922

COMPOSITIONS AND METHODS FOR DETECTING AN RNA VIRUS

ENVIROLOGIX INC., Portla...


(ii) a nicking enzyme,
(iii) dNTPs,
(iv) a detectable oligonucleotide probe, and
(v) a strand-displacement polymerase
under conditions permissive for the isothermal amplification of the cDNA; and
(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, wherein detection of the signal indicates the presence or quantity of the target polynucleotide present in the sample and failure to detect the signal indicates the absence of target polynucleotide in the sample.
US Pat. No. 10,795,972

METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR LOCOMOTOR SYSTEM CONDITIONS

PSOMAGEN, INC., Rockvill...

1. A method for characterizing an arthritic condition, the method comprising:for each sample of a set of biological samples from a set of subjects comprising at least one subject associated with the arthritic condition:
determining a microorganism nucleic acid sequence, comprising:
selecting a primer for a nucleic acid sequence, and amplifying nucleic acid material from the sample using the selected primer; and
determining an alignment of the microorganism nucleic acid sequence to a reference nucleic acid sequence;
generating a microbiome feature dataset, comprising diversity features extracted from at least one of a microbiome composition diversity dataset and a microbiome functional diversity dataset, based on the alignments;
transforming the microbiome feature dataset into a characterization model for the arthritic condition;
based upon the characterization model, generating a therapy model operable to determine a therapy to improve a state of the arthritic condition; and
providing the therapy to a subject with the arthritic condition in accordance with the therapy model, wherein the therapy is operable to modulate microbiome composition to improve the state of the arthritic condition.
US Pat. No. 10,792,642

CATALYST AND PREPARATION METHOD THEREOF, AND METHOD FOR PREPARING ISOBUTYLENE BY APPLYING THE SAME

Fushun Research Institute...

1. A catalyst having a core-shell structure, comprising:a core comprising an amorphous silica-alumina particle and/or a particle aggregate of a plurality of amorphous silica-alumina particles;
a shell comprising aluminum oxide containing silicon and tin,
wherein a weight ratio of the aluminum oxide containing silicon and tin to the amorphous silica-alumina is 1:60-1:3,
wherein, in the aluminum oxide containing silicon and tin, on the basis of the weight of the aluminum oxide containing silicon and tin and calculated as elements, a content of silicon is 0.5-2 wt %, and a content of tin is 0.2-1 wt %, and
wherein the amorphous silica-alumina has a specific surface area of 240-450 m2/g and a pore volume of 0.4-0.9 mL/g.
US Pat. No. 10,793,667

CURABLE COMPOSITIONS, PRODUCTS AND ARTICLES FORMED THEREFROM, AND METHODS OF FORMING THE SAME

Covestro Deutschland AG, ...

1. A method comprising:contacting a morpholinedione with an isocyanate to form a resin composition; and
reacting the resin composition with an amine to form a curable composition.
US Pat. No. 10,793,923

COMPOSITIONS AND METHODS FOR DETECTION OF BK VIRUS

Roche Molecular Systems, ...

1. A method of detecting BK virus in a sample, the method comprising: (a) performing an amplifying step comprising contacting the sample with a set of primers to produce an amplification product, if a target nucleic acid of BK Virus is present in the sample; (b) performing a hybridization step comprising contacting the amplification product, if a target nucleic acid is present in the sample, with a probe; and (c) detecting the presence or absence of the amplification product, wherein the presence of the amplification product is indicative of the presence of BK virus in the sample, and wherein the absence of the amplification product is indicative of the absence of BK virus in the sample; wherein the set of primers consists of a first primer consisting of SEQ ID NO:4, and a second primer consisting of SEQ ID NO:5, and wherein the probe consists of SEQ ID NO:3 and optionally a label.
US Pat. No. 10,792,643

METHOD FOR PRODUCING OXIDE CATALYST AND METHOD FOR PRODUCING UNSATURATED NITRILE

ASAHI KASEI KABUSHIKI KAI...

1. A method for producing an oxide catalyst comprising Mo, V, Sb, and Nb, the method comprising:a material preparation step comprising
a sub-step (I) of preparing an aqueous mixed liquid (A) comprising Mo, V, and Sb,
a sub-step (II) of adding hydrogen peroxide to the aqueous mixed liquid (A), thereby facilitating oxidation of the aqueous mixed liquid (A) and obtaining an aqueous mixed liquid (A?), and
a sub-step (III) of mixing the aqueous mixed liquid (A?) and a Nb material liquid (B), thereby obtaining an aqueous mixed liquid (C);
a drying step of drying the aqueous mixed liquid (C), thereby obtaining a dried powder; and
a calcination step of calcining the dried powder under an inert gas atmosphere,
wherein a time elapsed from addition of the hydrogen peroxide to the aqueous mixed liquid (A) to mixing the Nb material liquid (B) therewith is less than 5 minutes and
the aqueous mixed liquid (A?) before being subjected to the sub-step (III) has an oxidation-reduction potential of 150 to 350 mV.
US Pat. No. 10,792,899

MULTILAYER FILMS AND LAMINATES AND ARTICLES COMPRISING THE SAME

Dow Global Technologies L...

1. A biaxially oriented, multilayer polyethylene film comprising:Layer A which is a sealant layer having a top facial surface and a bottom facial surface and comprising a first ethylene-based polymer composition, wherein the first ethylene-based polymer composition has a density of at least 0.900 g/cm3, an IHDF>95 of 20-60 kg/mol, and a MWHDF >95 of greater than 130 kg/mol, wherein Layer A comprises at least 50 weight percent of the first ethylene-based polymer composition based on the weight of Layer A; and
Layer B having a top facial surface and a bottom facial surface, wherein Layer B comprises one or more additional polyethylenes;
wherein the top facial surface of Layer B is in adhering contact with a bottom facial surface of Layer A, wherein the density of the first ethylene-based polymer composition is at least 0.002 g/cm3 less than the density of Layer B.
US Pat. No. 10,792,644

CATALYST TA-NB FOR THE PRODUCTION OF 1,3-BUTADIENE

IFP Energies nouvelles, ...

1. A catalyst comprising a mesoporous oxide matrix, said matrix comprising at least one oxide of an element X that is silicon or titanium, alone or in a mixture, said catalyst comprising tantalum and niobium, having a tantalum mass of 0.1 to 30% of the mass of the mesoporous oxide matrix, a niobium mass of 0.02 to 6% of the mass of the mesoporous oxide matrix, the content by mass of the tantalum element in said catalyst being greater than or equal to the content by mass of the niobium element in said catalyst, said catalyst being prepared by consecutive introduction of the niobium element and then the tantalum element.
US Pat. No. 10,792,900

SHEET FOR ABSORBING MOISTURE

DYNIC CORPORATION, Kyoto...

1. A moisture-absorbing sheet comprising a hygroscopic molded article containing a resin component and a hygroscopic agent,(1) the hygroscopic agent comprising calcium oxide-based particles having a specific surface area of 0.5 m2/g to 1.7 m2/g and an average particle diameter of 0.5 ?m to 50 ?m;
(2) the resin component comprising a fibrillated fluororesin; and
(3) the sheet having
a) a weight increase ratio of 1% or less after being allowed to stand for 2 hours in an atmosphere at a temperature of 20° C. and a relative humidity of 65%; and
b) a weight increase ratio of 5% or more after being allowed to further stand for 36 hours after being allowed to stand for 36 hours in an atmosphere at a temperature of 20° C. and a relative humidity of 65%.
US Pat. No. 10,793,925

LACTOBACILLUS PARACASEI FOR THE PRODUCTION OF CONJUGATED LINOLEIC ACID, NUTRITIONAL AND PHARMACEUTICAL PREPARATIONS CONTAINING IT AND USES THEREOF

ALFASIGMA S.P.A., Bologn...

1. A process of producing a lyophilized preparation of Lactobacillus paracasei LMG S-26420 strain deposited at Belgian Coordinated Collection of Microorganism,BCCM/LMG Bacteria Collection,
Universiteit Gent,
Laboratorium voorMicrobiologies,
K.L. Ledeganckstraat, 35
9000 Gent,with the accession number LMG S-26420, wherein the deposited Lactobacillus paracasei LMG S-26420 strain is capable of converting linoleic acid to conjugated linoleic acid in a percentage higher than 30%, said method comprising the steps of:inoculating the Lactobacillus paracasei LMG S-26420 strain in to a suitable culture broth, separating the bacterial mass of the strain from the culture broth by centrifugation and lyophilizing the centrifuged Lactobacillus paracasei LMG S-26420 strain.
US Pat. No. 10,792,645

TRANSITION-METAL-SUPPORTING INTERMETALLIC COMPOUND, SUPPORTED METALLIC CATALYST, AND AMMONIA PRODUCING METHOD

JAPAN SCIENCE AND TECHNOL...

1. A transition metal-supporting intermetallic compound having a transition metal supported on an intermetallic compound represented by the following formula (1):A5X3  (1)
wherein:
A represents a rare earth element; and
X represents Si or Ge,
wherein a ratio of the transition metal to the intermetallic compound is 0.1% by mass or more and 30% by mass or less.
US Pat. No. 10,793,926

GLYCOSYL HYDROLASE XYLANASES, COMPOSITIONS AND METHODS OF USE FOR EFFICIENT HYDROLYSIS AND PROCESSING OF XYLAN

1. A composition for lignocellulosic biomass digestion, the composition comprising:an isolated glucuronic acid (GA)-independent glycoside hydrolase family 30 subfamily 8 (GH30-8) enzyme exhibiting xylanase activity, wherein the enzyme comprises the amino acid sequence (W or Y)(W or F)W(I or V or F)(not R)(not R) of SEQ ID NOs:69-80 within the ?8-?8 loop of the enzyme; and
lignocellulosic biomass material.
US Pat. No. 10,792,390

PARTICLES

MicroVention, Inc., Alis...

1. An embolic composition including:embolic particles including a reaction product of a prepolymer solution including:
a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof;
at least one monomer, and
a visualization agent,
wherein the embolic particles have a diameter between about 40 ?m and about 1,500 ?m.
US Pat. No. 10,793,671

ALIPHATIC POLYCARBONATE MACROPOLYOL AND ALIPHATIC POLYCARBONATE-COAROMATIC POLYESTER MACROPOLYOL

LOTTE CHEMICAL CORPORATIO...

1. A method for producing an aliphatic polycarbonate macropolyol, comprising:(a) condensing HOAOH in the presence of a base catalyst and an agent comprising DMC to prepare a condensation product, wherein the condensation product is an aliphatic polycarbonate with a number average molecular weight of 10000 or higher, the condensing step comprising:
(a1) reacting the HOAOH with the agent at ambient pressure at a first temperature to form oligomers, wherein, in the oligomers, —OH and —OCH3 are present in a ratio of about 1:1, and
(a2) forming the condensation product from the oligomers at an elevated temperature higher than the first temperature and at a reduced pressure lower than ambient pressure; and
(b) transesterifying the condensation product with Z(OH)a to form a final product, wherein the final product is an aliphatic polycarbonate with a number average molecular weight lower than that of the condensation product,
wherein A is a substituted or unsubstituted C3-C60 alkylene or a combination of two or more substituted or unsubstituted C3-C60 alkylenes,
wherein a is an integer from 2 to 4, provided that, when a is 2, Z is a substituted or unsubstituted C3-C60 alkanediyl, when a is 3, Z is a substituted or unsubstituted C3-C60 alkanetriyl, and when a is 4, Z is a substituted or unsubstituted C4-C60 alkanetetriyl,
wherein the aliphatic polycarbonate macropolyol comprises:
—OAO— and Z(O—)a as repeating units and a linker, the linker comprising carbonyl (—C(O)—), wherein the repeating units —OAO— and Z(O—)a are linked to each other via the linker or are bonded to hydrogen to form terminal —OH groups,
wherein the transesterifying step occurs in the presence of the base catalyst used in the condensing step, and
wherein the number average molecular weight of the condensation product is at least 10 times higher than that of the final product.
US Pat. No. 10,792,903

TRANSFER SHEET AND HARD COAT BODY USING SAME

Dai Nippon Printing Co., ...

1. A hard coated article comprising: at least a hard coat layer, a primer layer, an adhesive layer, and a resin molded article in this order,wherein the hard coat layer is formed of a cured product of a resin composition containing a curable resin, and
the primer layer is formed of a binder resin containing polyurethane having a mass average molecular weight of 50,000 to 80,000; wherein the polyurethane is a copolymer consisting of an acrylic component and a urethane component with 5 to 20% by mass of the acrylic component, and
wherein the urethane component is a polycarbonate-based urethane.
US Pat. No. 10,792,648

MIXED METAL LARGE CRYSTAL MOLECULAR SIEVE CATALYST COMPOSITIONS, CATALYTIC ARTICLES, SYSTEMS AND METHODS

BASF Corporation, Florha...

1. A catalytic article comprising a substrate having at least one washcoat thereon so as to contain both a first molecular sieve promoted with copper and a second molecular sieve promoted with iron, the first and second molecular sieves having a d6r unit and the first molecular sieve having cubic shaped crystals with an average crystal size of about 0.5 to about 2 microns, wherein the weight ratio of the copper-promoted molecular sieve to the iron-promoted molecular sieve is about 1:1 to about 4:1, the catalytic article effective to catalyze the reduction of nitrogen oxides in the presence of a reductant, wherein the catalytic article has an N2O make of about 7 ppm or less at 225° C. and an N2O make of about 4 ppm or less at 550° C. after hydrothermal aging in the presence of 10% H2O at 750° C. for 5 hours.
US Pat. No. 10,792,649

AUTOMATED BIONANOCATALYST PRODUCTION

Zymtronix, LLC, Ithaca, ...

1. An automated method of producing self-assembled bionanocatalysts (BNC), comprising combining an MNP preparation with an enzyme preparation in an automated machine, wherein said machine comprises an MNP disruptor and a BNC mixer, wherein said BNC mixer comprises a mixing tee or a mixing coil;wherein said automated machine performs the steps of
(a) disrupting MNPs in said MNP preparation with said MNP disruptor; and
(b) mixing said enzyme preparation with said disrupted MNP preparation using said BNC mixer;
wherein said mixing step causes a plurality of enzymes from said enzyme preparation to become magnetically immobilized within said MNPs to form said BNCs; wherein said magnetically immobilized enzymes are operable to catalyze the conversion of a diffusible substrate to a diffusible product.
US Pat. No. 10,793,930

FERRITIC-AUSTENITIC TWO-PHASE STAINLESS STEEL MATERIAL AND METHOD FOR MANUFACTURING SAME

1. A ferritic-austenitic duplex stainless steel material comprising, in mass %,C: 0.005% to 0.050%,N: 0.05% to 0.30%,Si: 0.1% to 1.5%,Mn: 0.1% to 7.0%,P: 0.005% to 0.100%,S: 0.0001% to 0.0200%,Cr: 18.0% to 28.0%,Cu: 0.1% to 3.0%,Ni: 0.1% to 8.0%,Mo: 0.1% to 5.0%,Al: 0.001% to 0.050%,B: 0.0001% to 0.0200%,Ca: 0.0001% to 0.0100%, anda balance consisting of Fe and inevitable impurities, whereinan austenitic phase has an area ratio ranging from 30% to 70%, and
formulae (I) and (II) below are satisfied,
1.03?[% Cr*F]/[% Cr]?1.40  Formula (I)
1.05?[% Mn*A]/[% Mn]?1.80  Formula (II)where [% symbol of an element] indicates a content (mass %) of the element in the steel, [% symbol of an element*F] indicates a content (mass %) of the element in a ferrite phase, and [% symbol of an element*A] indicates a content (mass %) of the element in the austenitic phase.
US Pat. No. 10,793,675

METHOD OF MAKING POLYETHERIMIDE

SABIC GLOBAL TECHNOLOGIES...

1. A method of making a polyetherimide comprising:combining a bisphenol A dianhydride, p-phenylene diamine and a halogenated aromatic solvent to form a reactant solution;
heating the reactant solution to a temperature of 205° C. to 330° C. at a pressure sufficient to prevent boiling to afford a reaction solution;
removing water from the reaction solution;
maintaining the reaction solution at a temperature of 205° C. to 330° C. and a pressure sufficient to prevent boiling for 10 minutes to 5 hours to form a product mixture comprising the polyetherimide and solvent; and
isolating the polyetherimide.
US Pat. No. 10,792,395

METHODS AND DEVICES FOR THE PRODUCTION OF DECELLULARISED TISSUE SCAFFOLDS

UCL Business Ltd, London...

1. A method of producing a decellularised tissue scaffold comprising;(i) providing a tissue sample selected from the group consisting of kidney, muscle, bone, adipose, cartilage, lung, bladder, cornea, skin, liver, spleen, placenta, intestine, pancreas, prostate, breast and heart,
(ii) treating the tissue sample with an osmotic reagent, and
(iii) treating the tissue sample obtained from step (ii) with a detergent,
wherein steps (ii) and (iii) are repeated, and wherein the tissue sample is subjected to oscillation in a single linear dimension with a displacement of 1 mm or more and a frequency of 3 to 100 Hz during steps (ii) and (iii), said oscillation subjecting the tissue sample to a g-force of 6 to 50 ms?2 thereby producing a decellularised tissue scaffold.
US Pat. No. 10,793,932

METHOD FOR MANUFACTURING LIGHTWEIGHT STEEL PLATE WITH ULTRAHIGH STRENGTH AND HIGH TOUGHNESS

UNIVERSITY OF SCIENCE AND...

1. A method for manufacturing a steel plate, comprising the following steps:(1) smelting: obtaining a molten steel by a converter furnace, an electric furnace or a vacuum induction furnace, wherein the molten steel comprises, in percent by weight: 0.30-0.45 wt % C, 1.0-2.0 wt % Si, 2.0-4.0 wt % Al, 6.0-7.0 wt % Mn, 0.30-0.50 wt % V, 0.02-0.05 wt % Nb, 0.001-0.005 wt % B, ?0.003 wt % N, ?0.015 wt % P, ?0.005 wt % S, Fe, and inevitable impurities;
(2) casting: obtaining a slab by continuous casting based on the molten steel obtained in step (1), or obtaining an ingot by mold casting based on the molten steel obtained in step (1);
(3) hot rolling: heating the slab or the ingot at 1050-1200° C., performing the hot rolling on the slab or the ingot to a thickness of 40-80 mm in 3-10 times by a roughing mill, and further performing the hot rolling on the slab or the ingot at 1050-1200° C. to a thickness of 4-6 mm in 5-10 times by a finishing mill to obtain a hot rolled slab or a hot rolled ingot, and cooling a temperature of the hot rolled slab or the hot rolled ingot to room temperature, wherein a thickness reduction for each hot rolling pass is controlled between 20-40%, and a total thickness reduction in a finishing stage is greater than 90%; and
(4) tempering: performing a tempering process on the hot rolled slab or the hot rolled ingot, and cooling the temperature of the hot rolled slab or the hot rolled ingot to room temperature to obtain the steel plate,
wherein a density of the steel plate is less than 7.4 g/cm3, a yield strength of the steel plate after heat treatment is greater than or equal to 1300 MPa, a tensile strength of the steel plate is greater than or equal to 2000 MPa, an elongation of the steel plate is greater than or equal to 12%, an impact energy of the steel plate at ?40° C. is greater than 45 J, the steel plate can pass a test of cold bending to 90° angle without cracking and succeed in defending a shot of 53-type 7.62 mm steel-core bullet.
US Pat. No. 10,792,652

METHODS TO REJUVENATE A DEACTIVATED HYDROFORMYLATION CATALYST SOLUTION

Dow Technology Investment...

1. A method to rejuvenate a deactivated hydroformylation catalyst solution comprising rhodium, polydentate phosphine ligands, and polydentate phosphine ligand degradation products, the method comprising: adding a peroxide to the deactivated hydroformylation catalyst solution.
US Pat. No. 10,792,909

LASER-ENGRAVABLE PAD PRINTING PLATE

Flint Group Germany GmbH,...

1. A laser-engravable pad printing plate comprising:(a) a metal support,
(b) an adhesion layer,
(c) a laser-engravable recording layer having a layer thickness of 20 ?m to 200 ?m obtained from a mixture comprising
(c1) 40 to 95 wt % of a polyvinyl alcohol,
(c2) 5 to 50 wt % of an IR absorber,
(c3) 0 to 30 wt % of an inorganic filler,
(c4) 0.1 to 20 wt % of a crosslinker, and
(c5) 0 to 10 wt % of further additives,
(d) a cover film,
wherein the crosslinker (c4) is selected from the group consisting of polyfunctional isocyanates, mono- or polyfunctional aldehydes, polyfunctional epoxides, polyfunctional carboxylic acids and polyfunctional carboxylic anhydrides; and
wherein the laser-engravable recording layer is obtained in a process comprising chemically crosslinking the crosslinker with the polyvinyl alcohol.
US Pat. No. 10,793,680

BRIDGED SILICONE RESIN, FILM, ELECTRONIC DEVICE AND RELATED METHODS

Dow Silicones Corporation...

1. A bridged silicone resin having the general formula (1):(HSiO3/2)x(SiO3/2—X—SiO3/2)y  (1)
wherein x and y are each from >0 to <1 such that x+y=1; and wherein X is divalent group comprising a silarylene group.
US Pat. No. 10,793,936

HIGH STRENGTH GALVANIZED STEEL SHEET HAVING EXCELLENT SURFACE QUALITIES, PLATING ADHESION, AND FORMABILITY, AND METHOD FOR MANUFACTURING SAME

POSCO, Pohang-si, Gyeong...

4. A method for a high strength galvanized steel sheet having excellent surface qualities, plating adhesion, and formability, the method comprising:forming a steel slab comprising 0.1-0.3 wt % of C, 1-2.5 wt % of Si, 3.05-8 wt % of Mn, 0.001-0.5 wt % of sol. Al, 0.04 wt % or less of P, 0.015 wt % or less of S, 0.02 wt % or less of N (excluding 0 wt %), 0.1-0.7 wt % of Cr, 0.1 wt % or less of Mo, (48/14)*[N] to 0.1 w t% of Ti, 0.005-0.5 wt % of Ni, 0.01-0.07 wt % of Sb, 0.1 wt % or less of Nb, and 0.005 wt % or less of B, with the remainder being Fe and other inevitable impurities;
reheating the steel slab at a temperature of 1100-1300° C.;
ultimately hot rolling the re-heated steel slab at a Ar3 transformation point or higher;
coiling the hot rolled steel sheet at a temperature of 700° C. or lower;
pickling and then cold rolling the coiled steel sheet;
recrystallization annealing the cold rolled steel sheet at a dew point temperature of ?60° C. to 39° C. and at a temperature of 750-950° C. for 5 to 120 seconds;
cooling the annealed cold-rolled steel sheet to 200-600° C. at an average cooling rate of 2-150° C/s;
reheating or cooling the cooled steel sheet to a temperature of (galvanizing bath temperature-20° C.) to (galvanizing bath temperature +100° C.);
plating the reheated or cooled steel sheet by dipping in a galvanizing bath maintained at a temperature of 450-500° C.; and
further comprising, prior to the annealing, plating a surface of the annealed cold-rolled steel sheet containing at least one component selected from the group consisting of Fe, Ni, Co and Sn with a coating weight of 0.01-2 g/m2;
wherein the cooling is divided into a first cooling and a second cooling, cooling to 400-740° C. is performed in the first cooling, and cooling to 200-600° C. is performed in the second cooling, and
wherein the second cooling rate is higher than the first cooling rate.
US Pat. No. 10,793,937

STEEL FOR INDUCTION HARDENING

NIPPON STEEL CORPORATION,...

1. A steel for induction hardening comprising, as a chemical composition, by mass %:C: 0.40% to 0.60%;
Si: 0.01% to 0.4%;
Mn: 0.2% to less than 1.0%;
Cr: 0.01% to less than 0.5%;
Al: 0.11% to 0.17%;
S: more than 0.03% to 0.07%;
N: 0.0030% to 0.0075%;
P: less than 0.05%;
B: 0% to 0.005%;
Mo: 0% to 0.2%;
Ni: 0% to 1.0%;
Cu: 0% to 1.0%;
Ca: 0% to 0.005%;
Mg: 0% to 0.005%;
Zr: 0% to 0.005%;
Rem: 0% to 0.005%;
Ti: 0% to 0.2%;
Nb: 0% to 0.2%;
V: 0% to 0.35%;
Sb: 0% to 0.015%;
Te: 0% to 0.2%;
Pb: 0% to 0.5%;
Bi: 0% to 0.5%; and
a remainder including Fe and impurities,
wherein the chemical composition satisfies Expressions (1) to (3),
at a ¼ position of a diameter of the steel, an area fraction of AlN having an equivalent circle diameter of more than 200 nm is 20% or less of an area fraction of all AlN having an equivalent circle diameter of 40 nm or more, and
at the ¼ position of the diameter of the steel, a number density of Mn sulfide-based inclusions having a maximum diameter of 0.3 ?m or more and 10 ?m or less is 100 pieces/mm2 or more and 2500 pieces/mm2 or less:
0.000330?Al×N?0.000825  (1)
4.6?Mn/S?14.0  (2)
15.5?(?1.40×Al+0.0175)×(214×(C+(1/7)×Si+(?)×Mn+(1/9)×Cr)?211)?25.65  (3)
where the symbols “C”, “Si”, “Mn”, “Cr”, “Al”, “N”, and “S” included in Expression (1), Expression (2), and Expression (3) respectively indicate amounts of C, Si, Mn, Cr, Al, N, and S by unit mass %.
US Pat. No. 10,793,682

METHOD FOR MANUFACTURING HYDROPHILIC CELLULOSIC NANOFIBERS IN LOW-POLARITY ENVIRONMENTS AND MATERIALS COMPRISING SUCH NANOFIBERS

1. A method for manufacturing hydrophilic nanofibrous biopolymers comprising the steps of(a) providing an aqueous suspension of said biopolymer;
(b) combining said aqueous suspension with a diluent to obtain a ternary system,
said diluent being selected from the group consisting of mineral oils, silicon oils, natural oils,
said diluent having a lower vapour pressure than water (for temperatures between 0-100° C. and pressures between 0-1 atm);
(c) reducing the water content from said ternary system by evaporation below 30 wt %;
(d) optionally further processing the obtained suspension of hydrophilic biopolymers in diluent;
and wherein said aqueous suspension and said diluent are free of surfactants.
US Pat. No. 10,793,939

NICKEL BASED SUPERALLOY WITH HIGH VOLUME FRACTION OF PRECIPITATE PHASE

United Technologies Copor...

1. A material, comprising:a nickel based superalloy with greater than about 40% by volume of gamma prime precipitate in which the precipitate structure is greater than about 0.7 micron size, wherein the nickel based superalloy includes rhenium and about 8-12.5% tantalum.
US Pat. No. 10,793,940

FLUX COMPOSITIONS FOR STEEL GALVANIZATION

FONTAINE HOLDINGS NV, Ho...

1. A flux composition for treating a metal surface to be coated in a hot dip galvanization process using a molten zinc-based galvanizing bath comprising:from 4 wt. % to 24 wt. % aluminum,
from 0.5 wt. % to 6 wt. % magnesium, and
the rest being essentially zinc,wherein the flux composition comprises:(a) more than 40 wt. % and less than 70 wt. % zinc chloride,
(b) from 10 wt. % to 30 wt. % ammonium chloride,
(c) more than 10 wt. % and less than 25 wt. % of a set of at least two alkali or alkaline earth metal halides, wherein the set of at least two alkali or alkaline earth metal halides is a set of at least two alkali metal chlorides, and wherein said set of at least two alkali metal chlorides comprises sodium chloride and potassium chloride in a KCl/NaCl weight ratio from 3.0 to 8.0;
(d) from 0.1 wt. % to 2 wt. % lead chloride, and
(e) from 2 wt. % to 14 wt. % tin chloride, provided that the combined amounts of lead chloride and tin chloride represent at least 2.5 wt. % and at most 14 wt. % of said composition; andwherein the flux composition further comprises at least one of a non-ionic surfactant and a corrosion inhibitor.
US Pat. No. 10,793,685

COSMETIC COMPOSITION, COSMETIC, AND EXTERNAL PREPARATION FOR SKIN

Dow Toray Co., Ltd., Tok...

1. A composite silicone rubber particle, wherein a part or entire surface of the silicone rubber particle is covered by a fine particle, wherein a surface of the fine particle is modified by a compound that contains a quaternary ammonium salt, and wherein a methanol content in the composite silicone rubber particle is not greater than 10 ppm.
US Pat. No. 10,793,433

PROCESS FOR PRODUCING HYDROGEN PEROXIDE

Solvay SA, Brussels (BE)...

1. A process for manufacturing hydrogen peroxide for use in an industrial end use application, comprising:(a) catalytically hydrogenating at least one alkylanthraquinone, wherein the at least one alkylanthraquinone is present in the form of a working solution comprising the at least one alkylanthraquinone dissolved in at least one organic solvent, to obtain at least one corresponding alkylanthrahydroquinone;
(b) oxidizing the at least one alkylanthrahydroquinone to obtain :hydrogen peroxide;
(c) extracting the hydrogen peroxide formed in step (b) of the process from the working solution with water to form an aqueous solution of hydrogen peroxide and recycling the working solution from step (b) of the process to step (a) of the process;
(d) monitoring one or more process parameters of one or more of steps (a), (b), and (c) of the process; and
(e) controlling one or more of steps (a), (b)and (c) of the process based on the one or more monitored process parameters,wherein:the industrial end use application is located at a first site, steps (a), (b), and (c) of the process are performed at the first site in a reactor system having a production capacity of hydrogen peroxide of up to 20 kilo tons per year,
steps (d) and (e) are performed remotely from a control site and the remote control site is different from and located at a distance from the first site,
replacement of the working solution and the catalyst of steps (a), (b), and (c) is performed independently from each other and periodically, and
steps (d) and (e) include the remote operational control of the AO-process chemistry.
US Pat. No. 10,792,411

ACCELERATED METHOD FOR PREPARING PLATELET RICH PLASMA

1. A method for preparing platelet rich plasma comprising:a) exposing a sample of whole blood to an anti-coagulant and an inducer of Rouleaux formation, wherein the inducer of Rouleaux formation is a starch wherein a portion of the inducer of Rouleaux is conjugated to magnetic beads and another portion is present as unconjugated, wherein the ratio of the unconjugated starch to starch conjugated to magnetic beads is from 2:1 to 50:1;
b) subjecting the mixture from a) to a magnetic field such that red blood cells to settle to the bottom;
c) removing the plasma fraction from the top,wherein no centrifugation step is used, and wherein the plasma fraction contains at least 100,000 platelets and less than 100,000 red blood cells per microliter.
US Pat. No. 10,793,436

TWO-DIMENSIONAL TRANSITION METAL CHALCOGENIDE NANOSTRUCTURE, DEVICE INCLUDING THE SAME, AND METHOD OF PREPARING THE TWO-DIMENSIONAL TRANSITION METAL CHALCOGENIDE NANOSTRUCTURE

Samsung Electronics Co., ...

1. A method of preparing a two-dimensional (2D) transition metal chalcogenide nanostructure, the method comprising:preparing a 2D transition metal chalcogenide nanostructure by a reaction between a transition metal precursor and a chalcogen precursor in a composition comprising a solvent,
wherein the chalcogen precursor is a compound including a first bond connecting two neighboring chalcogen elements and a second bond connecting one of the two neighboring chalcogen element and a hetero-element adjacent thereto,
a binding energy of the second bond is about 110% or less of a binding energy of the first bond,
wherein the 2D transition metal chalcogenide nanostructure has single crystallinity and was made in solution.
US Pat. No. 10,793,437

METHOD FOR THE MANUFACTURE OF FE(II)P/FE(II)METP COMPOUNDS

Chemische Fabrik Budenhei...

1. A method for the manufacture ofcrystal water-free iron(II) orthophosphate of the general formula Fe3(PO4)2 or
crystal water-free iron(II) metal orthophosphate, iron(II) metal pyrophosphate or iron(II) metal metaphosphate, each of which is represented by the general formula FeaMetb(POc)d, where a is a number from 1 to 5, b is a number from >0 to 5, c is a number from 2.5 to 5, d is a number from 0.5 to 3 and Met represents one or more metals selected from the group consisting of K, Rb, Cs, Mg, Ca, Sr, Ba, the transition metals (d block), the metals and semimetals of the third, fourth and fifth main groups, and the lanthanoids or combinations of the above mentioned phosphates with the stages:a) manufacture of a mixture containing:i) iron compounds (A) selected from Fe(III) compounds, Fe(III)/Fe(II) compounds and mixtures of these in a percentage of 20% to 90% by weight of the mixture selected from the group consisting of oxides, hydroxides, oxide hydroxides, carbonates, carboxylates orthophosphates, phosphonates, metaphosphates, pyrophosphates, sulphates and mixtures of those mentioned above,
ii) reduction agent (B) in a percentage of 5% to 50% by weight of the mixture selected from the group consisting of phosphonic acid [H3PO3], phosphorus trioxide [P2O3], phosphinic acid [H3PO2], phosphorus tetroxide [P2O4], hypodiphosphoric acid [H4P2O6], diphosphoric acid [H4P2O5], hypodiphosphonic acid [H4P2O4], Fe salts and Met salts of the above mentioned acids and mixtures of the above as solids, aqueous solutions or suspensions,
iii) optional phosphate donor (C) in a percentage of 0% to 50% by weight of the mixture selected from phosphoric acid [H3PO4] as an aqueous solution, metal phosphate [Metx(PO4)z] or acid metal phosphate [MetxHY(PO4)z] with 1?x?4, 1?y?5 and 1?z?4 as a solid or aqueous solution or suspension, diphosphoric acid [H4P2O7], metaphosphoric acid [(HPO3)n] with n?3 or their salts, phosphorus pentoxide [P2O5] or mixtures of the above, where Met is defined as above,
iv) optional metal (Met) donor (D) in a percentage of 0% to 50% by weight of the mixture selected from metal compounds of one or more metals from the group consisting of K, Rb, Cs, Mg, Ca, Sr, Ba, the transition metals (d block), and the metals and semimetals of the third, fourth and fifth main group, and the lanthanoids, and selected from the oxides, hydroxides, oxide hydroxides, carbonates, oxalates, formates, acetates, citrates, lactates, orthophosphates, pyrophosphates and sulphates of the above mentioned metals and mixtures of these,
whereby the share of the weight of components (A) to (D) of the mixture is based on the percentage of the substances not including any solvent and/or suspension agent,
b) the mixture obtained, if it contains aqueous and/or organic solvents from step a), is dried at a temperature of 400° C. or less,
c) the mixture, dry or dried in step b), is treated at a temperature in the range from 400 to 1200° C.
US Pat. No. 10,793,701

BASE COMPOSITION FOR MICRONEEDLE PATCH AND MICRONEEDLE PATCH COMPRISING THE SAME

WIN COAT CORPORATION, Hs...

1. A base composition, comprising a first hydroxypropyl methylcellulose, a second hydroxypropyl methylcellulose and a polyvinylpyrrolidone/vinyl acetate copolymer, the viscosity of the first hydroxypropyl methylcellulose being 400 centipoises to 10,000 centipoises, and the viscosity of the second hydroxypropyl methylcellulose being 1 centipoise to 100 centipoises, wherein based on a total weight of the base composition, a total amount of the first hydroxypropyl methylcellulose and the second hydroxypropyl methylcellulose is 0.1 wt % to 3 wt %, a weight ratio of the first hydroxypropyl methylcellulose relative to the second hydroxypropyl methylcellulose is 1:0.1 to 1:1.2, and an amount of the polyvinylpyrrolidone/vinyl acetate copolymer is 0.25 wt % to 2 wt %.
US Pat. No. 10,797,288

SEPARATORS FOR ELECTROCHEMICAL CELLS

OPTODOT CORPORATION, Dev...

1. A porous separator for an electrochemical cell, the separator comprising:a hydrated aluminum oxide; and
an organic polymer that is covalently bonded to at least a portion of said hydrated aluminum oxide.
US Pat. No. 10,793,703

TIRE

BRIDGESTONE CORPORATION, ...

1. A tire having at least one member selected from the group consisting of a side reinforcing rubber layer and a bead filler made of a vulcanized rubber composition comprising a natural rubber and an amine-modified butadiene rubber having a vinyl bond content in a micro structure of 20 to 50% by mass as a rubber component and having a difference between a dynamic tensile storage modulus E? at 180° C. (A) and a dynamic tensile storage modulus E? at 25° C. (B) {E?(A)?E?(B)} of 2.0 MPa or more, the dynamic tensile storage moduli being measured under conditions of an initial tensile strain of 5%, a dynamic tensile strain of 1%, and a frequency of 52 Hz.
US Pat. No. 10,793,704

NITRILE COPOLYMER RUBBER COMPOSITION, CROSS-LINK RUBBER COMPOSITION, AND CROSS-LINKED RUBBER

ZEON CORPORATION, Tokyo ...

1. A nitrile copolymer rubber composition comprising a nitrile copolymer rubber (A) containing 22 to 45 wt % of ?,?-ethylenically unsaturated nitrile monomer units, a vinyl chloride resin (B) having an average polymerization degree of 1200 to 2200, and a liquid nitrile rubber (C), whereina ratio of content of the vinyl chloride resin (B) with respect to 100 parts by weight of the nitrile copolymer rubber (A) is 70 to 140 parts by weight.
US Pat. No. 10,793,960

ELECTROLYTIC BATH FOR PRODUCING ANTIBACTERIAL METAL COMPOSITE COATINGS OF ANTIBACTERIAL ZINC METAL PARTICLES (ZN/PMA)

1. An electrolytic bath composition for obtaining antibacterial metal composite coatings of zinc-antibacterial metal particles (Zn/AMP), comprising an ion source of zinc ions, antibacterial metal particles, a pH buffering agent, polyethylene glycol, benzylideneacetone, sodium benzoate, triethanolamine, and a cationic surfactant, wherein the electrolytic bath has a pH between 2 and 6, and wherein the cationic surfactant is selected from cetyltrimethylammonium hydrogensulfate (CTAHS), cetyl pyridium bromide (CPBR), or cetyl pyridium chloride (CTCL).
US Pat. No. 10,793,705

LATEX FORMULATION FOR MAKING ELASTOMERIC PRODUCTS

TOP GLOVE SDN. BHD., Kla...

1. A latex formulation for making an elastomeric product, comprising a mixture of:a) a base polymer; and
b) a cross-linker;
wherein the cross-linker is an admixture of:
a) an inorganic trivalent metal or inorganic trivalent metal-based compound;
b) polyethylene glycol having a molecular weight ranging from about 200 Da to about 200,000 Da; and
c) a hydroxide salt, wherein the hydroxide salt comprises at least one of potassium hydroxide, sodium hydroxide, or ammonium hydroxide;
wherein the cross-linker is included in the latex formulation in an amount of from about 1.5% to about 6% per hundred grams of the base polymer (phr), wherein the latex formulation includes 0.015 to 0.18 phr of the inorganic trivalent metal or trivalent metal-based compound, 0.3 to 1.8 phr of the polyethylene glycol, and 0.015 to 0.6 phr of the hydroxide salt; and
wherein the latex formulation has a pH from 9.5 to 10.5.
US Pat. No. 10,793,961

METHOD OF OBTAINING A 18 CARATS 3N GOLD ALLOY

The Swatch Group Research...

1. A gold alloy, the gold alloy being a bright 3N yellow gold alloy composition of 75% gold, 19% copper and 6% silver.
US Pat. No. 10,793,706

FLUORORUBBER COMPOSITION

NOK CORPORATION, Tokyo (...

1. A fluororubber composition comprising 10 to 50 parts by weight of wollastonite and 0.5 to 10 parts by weight of organic peroxide based on 100 parts by weight of peroxide-crosslinkable fluororubber,the wollastonite being needle-like or fibrous wollastonite having an average fiber diameter of 5 ?m or less and an average fiber length of 40 to 80 ?m, and
the wollastonite being surface-treated with an amino silane coupling agent.
US Pat. No. 10,796,781

SPATIAL GENOMICS WITH CO-REGISTERED HISTOLOGY

Clarapath, Inc., New Yor...

1. A method of obtaining information about a three dimensional biopsy specimen, comprising:a) mounting a three dimensional biopsy specimen on a microtome, said specimen havingbeen prepared as a specimen block having a blockface;
b) establishing a two dimensional (x, y) coordinate system co-planar to said blockface;
c) establishing a third coordinate system (z) perpendicular to said blockface, said third coordinate system (z) comprising a set of ordered, sequential sections of said specimen, said set of sections prepared by:
i) adhering a support to said specimen blockface;
ii) subsequent to said adhering step, cutting a section from said specimen co-planar with said blockface, and removing from said blockface said section adhered to said support thereby producing a support-mounted section having two dimensional (x,y) coordinates co-planar, with said support and having a support side and a section side, whereby said adhering, said cutting, and said removing results in an un-distorted support-mounted section;
iii) repeating steps (i) and (ii) for at least z=n times; and
iv) with each repetition of (i) and (ii) above, retaining said un-distorted support-mounted sections in sequential order of z=1?z=n to preserve a series of un-distorted support-mounted sections until said undistorted support-mounted sections are tagged with a corresponding coordinate (z);
d) removing a tissue sample from at least one of said known (x,y) points on at least one of said undistorted support-mounted section (z); and
e) analyzing said tissue sample, so as to obtain information about said three dimensional biopsy specimen.
US Pat. No. 10,793,451

METHOD FOR TREATING WATER USED IN OIL FIELD APPLICATIONS TO INHIBIT BACTERIAL GROWTH WITH METHYLAMMONIUM MONOMETHYLDITHIOCARBAMATE

BULK CHEMICAL SERVICES, L...

1. In a method of treating water used in an oil field application to inhibit bacterial growth by adding an effective amount of a biocide to the water, the improvement comprising adding an effective amount of methylammonium monomethyldithiocarbamate to the water to inhibit bacterial growth, the effective amount of methylammonium monomethyldithiocarbamate being at least 1000 ppm weight based on the total formulation.
US Pat. No. 10,793,708

PROPYLENE HOMOPOLYMER COMPOSITION FOR CAPACITOR FILM, METHOD FOR PRODUCING THE SAME, AND CAPACITOR FILM

MITSUI CHEMICALS, INC., ...

1. A propylene homopolymer composition for a capacitor film, comprising 50 to 99% by mass of a propylene homopolymer (A1) having characteristics (A-i) to (A-iii) below and 1 to 50% by mass of a propylene homopolymer (B1) produced using a Ziegler-Natta catalyst and having characteristics (B-i) to (B-ii) below (with a sum of the propylene homopolymer (A1) and the propylene homopolymer (B1) being 100% by mass), and having:(i) a melt flow rate (MFR) of 1.0 to 10.0 g/10 min, and
(ii) a chlorine content of 2 ppm by mass or less,
wherein
(A-i) a mesopentad fraction (mmmm) measured by 13C-NMR is 0.930 or more,
(A-ii) a half width of an elution peak measured by temperature rising elution fractionation (TREF) is less than 4.0° C.,
(A-iii) a molecular weight distribution Mw/Mn measured by GPC is less than 3.0,
(B-i) a mesopentad fraction (mmmm) measured by 13C-NMR is 0.950 or more, and
(B-ii) a molecular weight distribution Mw/Mn measured by GPC is 3.8 or more.
US Pat. No. 10,796,783

METHOD AND SYSTEM FOR MULTIPLEX PRIMER DESIGN

PSOMAGEN, INC., Rockvill...

1. A method for selection of a primer set for simultaneous amplification of a set of nucleic acid target sequences, comprising:receiving a biological sample comprising the set of nucleic acid target sequences associated with a set of different targets;
at a computing system, identifying a set of candidate fragments upon performance of a comparison operation with the set of nucleic acid target sequences;
within the set of candidate fragments, identifying a forward subset of unique forward candidates and a reverse subset of unique reverse candidates;
at the computing system, reducing the forward subset of unique forward candidates and the reverse subset of unique reverse candidates upon performance of a filtering operation, thereby generating a reduced forward subset and a reduced reverse subset that satisfy a set of primer criteria;
at the computing system, with the reduced forward subset and the reduced reverse subset, performing an in silico search operation, wherein the in silico search operation includes a base mismatch criterion;
at the computing system, according to outputs of the in silico search operation and the base mismatch criterion, generating a set of candidate degenerate primers;
at the computing system, generating a reduced set of candidate degenerate primers upon filtering the set of candidate degenerate primers according to the set of primer criteria;
from the reduced set of candidate degenerate primers, selecting forward primer subsets that amplify the set of nucleic acid target sequences and identifying a reverse primer subset for each of the forward primer subsets with an in silico polymerase chain reaction (PCR) operation, thereby generating a set of forward primer-reverse primer subset groups;
at the computing system, from the set of forward primer-reverse primer subset groups, selecting the primer set according to a reaction criterion; and
within a laboratory environment, amplifying, with the primer set, the set of nucleic acid target sequences of the biological sample.